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ABSTRACT 
 
Mechanisms of Transcriptional Activation of Estrogen Responsive Genes in  
Breast Cancer Cells. (August 2006) 
Chien-Cheng Chen, B.S., National Taiwan University; 
M.S., National Taiwan University 
Chair of Advisory Committee: Dr. Stephen H. Safe 
 
 
Estrogen receptor (ER) acts as a ligand-activated transcription factor that 
regulates the expression of genes. The genomic mechanisms of ER action 
include ligand-induced dimerization of ER which binds estrogen responsive 
elements (EREs) in the promoters of target genes. There are also nongenomic 
mechanisms of ER action which are associated with membrane bound or cytosol 
ER-dependent activation of various protein-kinase cascades which also influence 
expression of target genes. 
Egr-1 is an immediate-early gene induced by 17β-estradiol (E2) in the 
rodent uterus and breast cancer cells. Deletion analysis of the Egr-1 promoter 
identified a minimal E2-responsive region that contained serum response 
element (SRE3) which bound Elk-1 and serum response factor (SRF) in gel 
mobility shift assays. Hormone-responsiveness of Egr-1 in MCF-7 cells was 
specifically inhibited by PD98059, a MAPKK inhibitor, but not by LY294002, an 
inhibitor of PI3-K. These results contrasted with the hormone-dependent 
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activation of the SRE in the c-fos promoter, which was inhibited by both PD98059 
and LY294002, suggesting that Egr-1, like c-fos, is activated through 
non-genomic pathways of estrogen action but through activation of different 
kinases. 
COUP-TFs are orphan nuclear receptors expressed in a variety of tissues 
where they regulate biological functions and organogenesis. In this study, we 
investigated coactivation of ERα by COUP-TF1 in cell lines transiently 
cotransfected with the pERE3 construct. COUP-TFI coactivated ERα-mediated 
transactivation, but unlike many other coactivators, COUP-TFI also enhanced 
transactivation of ERα when cells were cotransfected with the TAF1-ERα mutant 
or the 19c-ERα mutant. These data indicate that helix 12 of ERα is not required 
for coactivation by COUP-TFI when AF-1 of ERα is intact. However, when the 
AF-1 of ERα is deleted, the intact AF-2 function is required for coactivation by 
COUP-TFI. Analysis of multiple COUP-TFI deletion mutants showed that the 
DNA-binding domain and C-terminal region of COUP-TFI were important for 
coactivation of ERα. Point mutations of the DNA-binding domain of COUP-TFI 
resulted in loss of interactions with ERα, suggesting that the DNA-binding domain 
of COUP-TFI is important for its coactivation activity facilitating interactions with 
ERα. These results demonstrate that COUP-TFI coactivated ERα through a 
non-classical LXXLL-independent pathway. 
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CHAPTER I 
INTRODUCTION 
1.1 Cancer  
1.1.1 Breast Cancer 
Cancer, or neoplasia, is defined as “a group of diseases characterized by 
uncontrolled growth and spread of abnormal cells. If the spread is not controlled, 
it can result in death” (2). The word cancer is derived from the Latin for crab, 
because of the way it protrudes out from a central body like “the arms of a crab”. 
Even though cancer is often regarded as a single condition, it consists of more 
than 100 different diseases depending on its tissue of origin. Compared to the 
physiology of normal cells, cancerous cells exhibit deregulated homeostasis, 
uncontrolled growth, and invasiveness that are caused by cellular genetic or 
epigenetic alterations.   
Cancer is the second leading cause of death after heart disease in the U.S. 
About 1.3 million new cases of cancer will be diagnosed in 2005 and 
approximately 570,000 people will die from this disease. Approximately, 1 out of 
4 deaths are due to cancer. The 5-year relative survival rate of all cancers 
combined after first diagnosis is approximately 64%, whether in remission, under  
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treatment, or disease-free (2). Excluding cancers of the skin, breast cancer is the 
most commonly occurring cancer among women, accounting for nearly 1 in 3 
cancers diagnosed in US women. The estimated annual incidence of breast 
cancer worldwide is about one million cases with ~200,000 cases in United 
States (27% of all cancers in women) and ~320,000 cases in Europe (31% of all 
cancers in women) (243). Over the last two decades, the annual incidence rate in 
the U.S. has been increasing steadily (94). Nevertheless, in the last 10-15 years, 
breast cancer mortality has declined by 2.3% per year due to multiple factors, 
including improvements in cancer screening and novel and more effective 
treatment regimens (319). 
1.1.2 Structure and Development of the Mammary Gland 
The human breast, in common with the mammary glands of other species, 
contains both epithelial and mesenchymal components. The adult human 
mammary gland comprises a number of “tree-like” glandular structures formed by 
dichotomous branching of each of several ducts arising from the nipple. The 
major functional units of the mammary gland are the lobular structures 
comprising several small blindended ductules situated at the end of the terminal 
ducts and known as terminal ductal lobular units (TDLUs). The entire ductal 
system is lined by a continuous layer of luminal epithelial cells that are, in turn, 
surrounded by a layer of myoepithelial cells as shown in Figure 1-1. These 
myoepithelial cells are in direct contact with the basement membrane. The 
TDLUs are surrounded by delimiting fibroblasts and embedded in a specialized  
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Figure 1-1 The two distinct mechanisms of branching morphogenesis in the 
pubertal mouse mammary gland (366). 
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intralobular stroma. The luminal epithelial cells are the major proliferating cell 
type, whereas cell division or expression of antigens associated with proliferation 
is exceedingly rare in the myoepithelial cell type (251). The mammary glands of 
most mammalian species, including humans, are not fully developed and 
functional at birth. Unlike other organs such as the liver that are fully formed at 
birth, breast tissue in newborns consists of only a few tiny ducts extending a 
small distance from the nipple. Between birth and puberty, the growth of this 
structure is isometric in relation to the rest of the body, but at puberty, under the 
influence of ovarian and pituitary hormones, the gland undergoes the first phase 
of allometric growth. In early puberty, the primitive ductal structures begin to 
rapidly divide and multiply to form a treelike structure composed of many ducts. 
Once ovulatory menstrual cycles have begun, there is a cyclical increase in 
proliferation associated with the luteal phase, and the TDLUs become more 
elaborate in terms of the number of alveoli they contain with each successive 
ovulatory cycle (287). This progressive development of the epithelium continues 
to the age of approximately 35 years. The second phase of allometric growth in 
the mammary gland occurs during pregnancy. During early pregnancy, there is 
another burst of activity in which the ductal trees expand further and the number 
of ductules within the TDLUs increases greatly. These ductules differentiate to 
synthesize and secrete milk in late pregnancy and subsequent lactation. Once 
weaning has occurred, the mammary gland involutes; the secretory luminal 
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epithelial cells apoptose, the alveoli collapse and both epithelial and stromal 
components are remodeled to resemble the prepregnant state. 
The evidence from histological studies has shown that most human breast 
tumors are derived from TDLUs and have morphological characteristics of 
luminal epithelial cells (4). Significantly, more than 90% of breast tumors 
synthesize cytokeratins distinctive of the luminal phenotype, and greater than 
70% synthesize steroid hormone receptors, indicating that the luminal epithelial 
cell population must be regarded as the primary target for the oncogenic events 
leading to tumor formation (295).  
Breast tumorigenesis is thought to result from a ‘benign to malignant’ 
progression, in which the accumulation of genetic changes allows evolution from 
normal breast epithelium through benign and atypical proliferative lesions to 
carcinoma in situ and frankly invasive tumors (15). The lesions associated with 
the greatest risk of invasive breast cancer are, in order of increasing risk: 
hyperplasia of usual type, atypical ductal hyperplasia, lobular carcinoma in situ 
and ductal carcinoma in situ (DCIS). These premalignant lesions, with the 
exception of high grade DCIS, are frequently dependent on estrogen for their 
growth, as judged by the presence of the estrogen receptor (ER). ER-negative 
tumors often overexpress the genes encoding growth factor receptors, such as 
epidermal growth factor (EGFR or erbB1) and erbB2/HER2, and these are often 
overexpressed in DCIS of high nuclear grade (128). Premalignant lesions 
synthesizing ER might account for the success of the antiestrogens tamoxifen 
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and raloxifene in breast cancer prevention, because it is their progression to 
invasive breast cancer that might be inhibited (73). 
1.1.3 Risk Factors for Breast Cancer 
Based on epidemiological studies conducted in different populations, 
several well-established risk factors for breast cancer have been identified and 
these include: age, geographic location and socioeconomic status, reproductive 
events (menarche, menopause, pregnancy, breastfeeding), exogenous 
hormones (hormone replacement therapy and oral contraceptives), lifestyle risk 
factors (alcohol, diet, obesity and physical activity), mammographic density, 
history of benign breast disease, ionizing radiation, bone density, height, IGF-1 
and prolactin levels, chemopreventive agents, as well as genetic factors (high- 
and low penetrance breast cancer susceptibility genes) (See Table 1-1). 
Significant differences (5-10 fold) in the incidence and mortality rates of 
breast cancer have been observed between low- (Far East, Africa and South 
America) and high-risk (North America and Northern Europe) areas (244). These 
differences become even more profound after menopause (see section on age). 
For example, the overall breast cancer incidence in the Japan is 32.7 per 
100,000 and 19.5 per 100,000 in the eastern Africa area; however the incidence 
in the U.S. is 91.4 per 100,000, and the country with the highest incidence is the 
Netherlands (91.6/100,000). 
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Table 1-1 Summary of breast cancer risk factors (92). 
Breast Cancer Risk Factors Magnitude of Risk 
 Factors that increase breast cancer risk  
Well-confirmed Increasing age ++ factors 
Geographical region (USA and western countries) ++  
Family history of breast cancer ++  
Mutations in BRCA1 and BRCA2 genes ++  
 Mutations in other high-penetrance genes (p53, 
ATM, NBS1, LKB1) ++ 
Ionizing radiation exposure (in childhood) ++  
History of benign breast disease ++  
Late age of menopause ++  
Early age of menarche ++  
Nulliparity and older age at first birth ++  
High mammography breast density ++  
High insulin-like growth factor I (IGF-I) levels ++  
Hormonal replacement therapy +  
Oral contraceptives recent use +  
Obesity in postmenopausal women +  
Tall stature +  
Alcohol consumption (~1 drink/day) +  
High prolactin levels +  
High saturated fat and well-done meat intake + Probable factors 
Polymorphisms in low-penetrance genes +  
High socioeconomic status +  
 Factors that decrease breast cancer risk + 
Well-confirmed Geographical region (Asia and Africa) -- factors 
Early age of first full-term pregnancy --  
Higher parity --  
Breast feeding (longer duration) --  
Obesity in premenopausal women -  
Fruit and vegetables consumption -  
Physical activity -  
Chemopreventive agents -  
Non-steroidal anti-inflammatory drugs - Probable factors 
-  Polymorphisms in low-penetrance genes 
++ (moderate to high increase in risk) -- (moderate to high decrease in risk);  
+ (low to moderate increase in risk)  - (low to moderate decrease in risk) 
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The large variation of breast cancer incidence among or within different 
regions of the world may be attributed to genetic differences among populations 
and/or differences in lifestyle, including diet and environmental exposures. 
Studies on migrants have demonstrated that breast cancer incidence increases 
in people who move from a region with low breast cancer incidence (i.e. Asian 
countries) to other locations with higher breast cancer incidence (i.e. U.S.), as 
early as 10 years spent in the adopted country. This underlines the crucial 
contribution of the environmental and lifestyle factors to breast cancer risk (243, 
388) 
1.1.3.1 Lifestyle Risk Factors 
Among lifestyle risk factors, alcohol has been identified in numerous 
epidemiological studies as an important risk factor for breast cancer (312). 
Specific diets rich in well-done meats (387) or fat (351) are associated with a 
slightly increased risk for developing breast cancer, in some studies while a high 
intake of fruits and vegetables (187) or omega-3 PUFAs (289) decreases breast 
cancer risk. Obesity represents a high breast cancer risk factor for 
postmenopausal women, whereas in premenopausal women it is protective 
(140). 
Alcohol Intake  
Numerous epidemiological studies have found a positive association 
between alcohol intake and the risk of developing breast cancer in both pre and 
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postmenopausal women with an overall risk of 1.6. The risk increases linearly in 
a dose dependent manner up to an intake of 60 g (approx. 2-5 drinks) /day. For 
every 10 g-increment (approx. 0.75-1 drink) increase in daily consumption of 
alcohol the risk increases by 9% (312, 313). 
Diet  
The human diet contains a great variety of natural and chemical 
carcinogens and anti-carcinogens. Some of these compounds may act through 
the generation of free oxygen radicals, which can lead to DNA damage, or other 
deleterious components. Accordingly, well-done meat consumption has been 
associated with increased breast cancer risk due to the formation of carcinogens 
during the cooking process (323, 387). 
Physical Activity  
A recent meta-analysis of 19 case-control and four cohort studies 
investigating the relationship between physical activity and breast cancer risk has 
shown a consistent 20% reduction associated with physical activity performed in 
adolescence and young adulthood (12-24 years old). For each one-hour increase 
in recreational physical activity per week during adolescence, the breast cancer 
risk drops with 3%. Physical activity may reduce the risk by delaying the onset of 
menarche and modifying bioavailable hormone levels (119, 182).  
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1.1.3.2 Genetic Risk Factors 
Family history of breast cancer is a well-established major risk factor, 
especially in combination with mutations in high-penetrance breast cancer 
susceptibility genes, such as BRCA1 and BRCA2, p53, PTEN, ATM, NBS1 or 
LKB1, which are responsible for a high proportion of the hereditary breast 
cancers .  
BRCA1/ BRCA2  
Mutations in BRCA1 and BRCA2 (Breast Cancer 1 and 2), two of the most 
commonly implicated genes in hereditary breast cancer, are responsible for 
approximately 80-90% of all hereditary breast cancers, whereas they are rarely 
observed in sporadic breast cancer patients. Women who carry mutations in 
BRCA1 or BRCA2 have a considerably increased lifetime risk of breast cancer (~ 
80%), that is roughly ten times greater than that of the general population. 
BRCA1 and BRCA2 are tumor suppressor genes whose primary functions are 
the maintenance of genomic integrity including DNA repair and recombination, 
cell cycle control, and transcriptional regultion (79). Germline mutations in 
BRCA1 are associated with approximatively 42% of breast cancer families and 
81% of families with both ovarian and breast cancer (107). Germline mutations in 
BRCA2 are linked to approximately 76% of breast cancer families in which both 
females and males are affected. 
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p53  
p53 was the first tumor suppressor gene linked to hereditary breast cancer. 
p53 also plays an important role in maintaining genomic stability in response to 
DNA damage by inducing transient G1 cell cycle arrest or by triggering apoptosis. 
Women with germline mutation in p53 have an 18-fold higher risk for developing 
breast cancer before age of 45 compared to the general population, and the risk 
declines with age (110). 
There are also low penetrance genes (but present in a high percentage of 
individuals) that enhance breast cancer risk in combination with exogenous (e.g. 
diet, pollution) and endogenous (e.g. hormones) factors (281). These genes 
include phase I metabolic enzymes which metabolically activate carcinogens (e.g. 
the cytochrome P450 family proteins) and phase II enzymes which inactivate 
carcinogens (e.g. N-acetyl transferase and GST family proteins). Polymorphisms 
in both phase I and II enzymes involved in xenobiotic and endobiotic metabolism 
therefore may modulate the relative risk of breast cancer for an individual (234).  
1.1.3.3 Reproductive Risk Factors 
Breast cancer incidence is very low (less than 10 new cases per 100,000 
women) before age 25 and increases up to 100-fold by age 45 (141). This pattern 
suggests the involvement of reproductive hormones in the etiology of breast 
cancer (259), as hormone-independent cancers would not significantly increase 
during the active reproductive period. The number and timing of different 
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reproductive events in a woman's life modulates the risk of breast tumorigenesis. 
Several reproductive factors such as early age at menarche (before age 12), late 
age at menopause (after age 55), nulliparity and late age at first full term 
pregnancy increase breast cancer risk, whereas other factors including early age 
at first full-term pregnancy, higher parity and prolonged lactation are protective 
against breast cancer (92).  
The duration of lifetime exposure to ovarian hormones is closely related to 
breast cancer risk. Early age at menarche (less than 12 years of age versus more 
than 14 years of age) has been associated with an increase in breast cancer risk 
on the order of 10-20% magnitude (28, 41) and a 1-year delay in the onset of 
menarche is associated with a 5% reduction in risk for developing breast cancer 
in later life (142). Similarly, delayed menopause maximizing the number of 
ovulatory cycles lead to an increased breast cancer risk and each 1-year delay in 
the onset of menopause is associated with a 3% increase in risk (142). In 
contrast, surgically induced menopause before the age of 35 results in a 
decrease of breast cancer risk. These women have only 40% of the risk of 
women experiencing natural menopause. Mechanistically, it has been 
demonstrated that mammary epithelial cells proliferation, which is linked to breast 
cancer development, can be correlated with serum ovarian hormonal levels. 
Proliferation rates are low in the follicular phase of the menstrual cycle, when 
estradiol and progesterone levels are also low, whereas during the luteal phase 
proliferation rates are twofold higher and correlate with the significantly increased 
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ovarian hormone levels (259). The higher cellular proliferative activity confers a 
higher susceptibility of the mammary gland to be transformed by chemical 
carcinogens (286). After menopause, ovarian hormone levels drop and this 
correlates with a substantial decrease in mammary epithelial cell proliferation 
(29). Numerous prospective epidemiological studies also provide strong 
evidence for this mechanism. Accordingly, postmenopausal women who develop 
breast cancer have on average 15% higher levels of circulating estradiol than 
other postmenopausal women (29). 
Epidemiological studies have also firmly established associations between 
risk for breast cancer and other reproductive factors, including nulliparity (having 
no children) or low parity, late age at first birth, and breast feeding (160). After a 
transient increase in risk for breast cancer, peaking at about 5 years after giving 
birth (196), having at least one child is associated with a decrease in the 
long-term risk of developing breast cancer compared with risk among the 
nulliparous, and this protective effect increases with number of children. Each 
birth reduces the relative risk of breast cancer by an average of 7% (1). The 
reduction in risk per birth is greater for births at young ages, such that women 
who have their first birth before the age of 20 years have a 30% lower risk than 
women with a first birth after the age of 35 years (99). The protective effects of 
pregnancy against breast cancer is explained by the induction of complete 
differentiation of the breast that may markedly reduce the susceptibility of the 
fully differentiated mammary gland to carcinogens due to, at least in part, by 
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decreasing proliferative activity of parous epithelium (285). Another hypothesis is 
that the decrease risk may also be due to the altered hormonal environment 
during pregnancy, and these include specific molecular changes induced by 
estrogen and progesterone and decreased circulating growth hormones (288). 
 Breast feeding is also protective against breast cancer and this effect 
might be due to the suppression of ovulation, reducing exposure to ovarian 
hormones (29). 
1.1.4 Estrogens and Breast Tumorigenesis 
1.1.4.1 Synthesis and Catabolism of Estrogens 
Estrogens are a class of steroid hormones important for normal sexual 
development and are essential for the normal functioning of the female 
reproductive organs such as the ovaries and uterus which are required for 
childbearing and hormone synthesis. Estrogens help control a woman’s 
menstrual cycle and are important for the normal development of the breast. 
Estrogens are also required for maintenance of healthy bones and for 
cardiovascular health.  
Both estrogens and their androgen precursors are biosynthetically derived 
from cholesterol. In premenopausal women, the ovaries, which are under the 
cyclic control of pituitary gonadotropins, are the predominant source of serum 
estrogen, and only a small proportion of serum estrogen comes from peripheral 
organs. In contrast, the low levels of estrogen produced in postmenopausal 
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women comes predominantly from aromatization of adrenal and ovarian 
androgens in extragonadal tissues such as the liver, muscle, and fat tissues 
(293).  
Estrogens are catabolized mainly by hydroxylation that result in the 
formation of 2-hydroxyestrone and 2-hydroxyestradiol, 4-hydroxyestrone and 
4-hydroxyestradiol, and 16α-hydroxyestrone and 16α-hydroxyestradiol (catechol 
estrogens). Estrogens are also metabolized by subsequent methylation to form 
methoxyl estrogens (239) and methylation of 2- and 4-hydroxyestrogen by 
catechol O-methyltransferase is also observed (115) (see Figure 1-2).  
Catechol estrogens bind the estrogen receptor and have weak estrogenic 
activity in animals. In addition, catechol estrogens are capable of continuous 
metabolic redox cycling, which yields quinone intermediates as metabolites. 
Because of the formation of free radicals in this process and the covalent binding 
of these intermediates to DNA, it has been proposed that estrogens have 
genotoxic activity (194). After synthesis, estrogens are secreted into the blood 
stream where it binds with sex-hormone-binding globulin and albumin. Free 
estrogens diffuse into target tissues to exert their specific biological effects. 
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Figure 1-2 Pathways of estrogen synthesis and catabolism (68). 
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1.1.4.2 Estrogen Exposure and Breast Cancer Risk 
The clinical and epidemiological evidence for an obligate role of estrogen 
in human mammary gland development and tumorigenesis is considerable. 
Estrogens are crucial for the normal development of the human mammary gland. 
There is complete failure of breast development in the absence of intact ovarian 
function, and estradiol-replacement therapy is necessary to induce breast 
development (83). The obligate role for estradiol in mammary gland development 
is also supported by the studies using esrtogen receptor α (ERα) knockout mice 
(33). The mammary glands in ERα knockout mice comprise rudimentary ducts 
confined to the nipple area, which cannot undergo further development with 
estradiol treatment. 
In breast cancer, there is evidence that estrogen stimulates the growth of 
both premalignant and invasive tumors. More than 100 years ago Beatson first 
recorded the successful treatment of breast cancer by removal of the ovaries 
(224). Recent studies have shown that women who undergo ovariectomy early in 
life have a very low incidence of breast cancer (284). Similarly, rats and mice 
whose ovaries have been removed develop few if any breast tumors. Men, who 
do not have ovaries and have low blood levels of estrogen, have low breast 
cancer rates compared to women (333). 
An association between the risk of breast cancer and persistently elevated 
blood levels of estrogen has been found consistently in many studies. Several 
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endocrine-associated risk factors are regularly associated with an increased 
relative risk of breast cancer in postmenopausal women (68, 380). One of these 
factors is obesity, which is probably related to an increased production of 
estrogen by aromatase activity in breast adipose tissue (159). Another factor is 
an elevated blood level of endogenous estrogen (relative risk, 2.00 to 2.58) (158). 
An increased relative risk is also associated with higher-than-normal blood levels 
of androgens which can be directly converted by aromatase to estrone and 
estradiol, respectively. Elevated urinary levels of estrogens and androgens are 
also associated with an increased risk of breast cancer in postmenopausal 
women (237). All this evidence supports the hypothesis that cumulative, 
excessive exposure to endogenous estrogen over a woman's life span 
contributes to and may be a causal factor in breast cancer. 
1.1.4.3 Mechanism of Estrogen-dependent Carcinogenesis 
 Experimental, clinical, and epidemiologic data suggest that estrogens 
contribute to development of mammary cancer, but the mechanisms of this 
process are not well understood. Studies in rodents have demonstrated that 
estrogens or their catechol metabolites are carcinogens in various tissues, 
including the kidney, liver, uterus, and mammary glands. Figure 1-3 outlines two 
different but complementary pathways that may contribute to the carcinogenicity 
of estrogen (375).  
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Several mechanisms have been proposed to explain carcinogenicity of 
estrogens in breast cancer (53, 194). One of them is that the ER-mediated 
activity of E2 is related to induction of genes critical for regulating the cell cycle 
and stimulating cell proliferation. With each cycle of new DNA synthesis during 
mitosis, the chances for error in DNA replication without adequate repair are 
increased. As the proliferative process continues, mutations can accumulate and 
disrupt critical genes required for cellular proliferation, DNA repair, angiogenesis, 
or apoptosis, and these modifications can lead to neoplastic transformation (53, 
103). Once the breasr cancer intiation has taken place, these 
hormone-responsive transformed cells cannot repair any spontaneous or 
induced DNA damage with impaired function. The rapid proliferation activated by 
estrogens might promote the growth of transformed cells, leading to the 
development of detectable breast tumors. Estrogens can also stimulate 
production of autocrine and paracrine growth factors from the epithelium and 
stroma in the breast that can further contribute to breast cancer progression 
(315).
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Figure 1-3 Pathways for estrogen carcinogenesis (375). 
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Another mechanism involves oxidative metabolites of estrogens. The 
estradiol-3,4-quinone, which can form unstable adducts with adenine and 
guanine in DNA, results in destabilization of the glycosyl bond that links purine 
bases to the DNA backbone. Consequently, adenine and guanine, which are 
covalently bound to the estradiol quinone, are released from the DNA backbone 
and a naked, apurinic site is left behind in the DNA. Through the process of 
error-prone DNA repair, this site can form point mutations and serve as potential 
initiators of neoplastic transformation. In addition, reduction of estrogen quinones 
back to hydroquinones and catechols provides an opportunity for redox cycling 
which produces reactive oxygen species (53, 194) and probably accounts for the 
oxidative damage to lipids and DNA that is associated with estrogen treatment 
(185, 194).  
Estrogen has crucial roles in the proliferation of cancer cells in 
reproductive organs such as the breast and uterus. Estrogen-stimulated growth 
requires the ER which is a ligand-dependent transcription factor. It has been 
shown that about two-thirds of human breast tumors express higher levels of ER 
than normal breast tissues where ER levels are quite low. E2 and its intracellular 
receptor (ER) play a critical role in the formation and subsequent growth of 
mammary tumors and the molecular mechanisms of these responses are 
important for understanding the development and treatment of this disease. 
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1.2 Nuclear Receptor Superfamily 
1.2.1 Introduction 
Small lipophilic steroid hormones play an important role in the growth, 
differentiation, development and homeostasis of human tissues/cells. Most 
responses induced by these molecules are mediated through binding to nuclear 
receptors (NRs) that control gene expression (360). NRs exhibit a modular 
structure consisting of a C-terminal ligand dependent transcriptional activation 
domain (AF-2), a central DNA binding domain, and an N-terminal 
ligand-independent transcriptional activation domain (AF-1) Since the cloning of 
the first nuclear receptor for the glucocorticoid, more than 60 genes encoding 
nuclear receptors have been identified in vertebrates, arthropods and nematodes 
(344). Based on sequence similarity and evolutionary relatedness, the NR 
superfamily is divides into seven subfamilies, and within subfamilies there are 
further divisions into groups. In general, receptors within a group share at least 
80-90% identity within their DNA binding domains, and at least 40-60% identity 
within their ligand binding domains (223). 
1.2.2 Structures and Functions of NR Domains 
Nuclear receptors share a common modular structure with autonomous 
functional domains that can be interchanged between related receptors without 
loss of function (180). A typical nuclear receptor consists of a variable 
amino-terminal region (A/B domain), a conserved DNA-binding domain (DBD) or 
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region C, a linker region D, and a conserved E region that contains the 
ligand-binding domain (LBD). Some receptors contain an additional F domain in 
the C-terminal region which exhibits a highly variable sequence and whose 
structure and function are not well defined. Figure 1-4 is a schematic 
representation of a typical nuclear receptor.  
The A/B region is variable in both size and sequence and interacts with 
coactivators and/or other transcription factors in a cell- and promoter specific 
manner (34, 357). The A/B region in many receptors contains one constitutively 
active transcriptional activation function, referred to as AF-1 which contributes to 
ligand-independent activation of the receptor (337). The A/B domain is also a 
target for phosphorylation in many receptors including ER and PPARγ and this 
may result in activation or repression of its transcriptional activity (152, 155). 
The DBD or the C-region has the most conserved amino acid sequence 
among the members of the NR superfamily and is required for the recognition 
and binding of specific target sequences on DNA. The DBD has two highly 
conserved zinc-finger motifs spanning ~60-70 amino acids: C-X2-C-X13-C-X2-C 
and C-X5-C-X9-C-X2-C that are common to the entire family with the exception 
of two divergent members: DAX-1 and SHP (301, 381). In addition, the DBD has 
a COOH-terminal extension (CTE) that contains the so-called T and A boxes 
critical for specificity and polarity of NRs in DNA binding (134, 214). 
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Figure 1-4 Structural and functional organization of NRs (114).
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Each zinc-finger contains four highly conserved cysteine molecules that 
coordinate the binding of a zinc atom. Amino acids required for sequence 
specificity in DNA binding are present at the base of the N-terminal finger in a 
region termed the “P box”, and residues of second zinc finger that form the 
so-called “D box” are involved in dimerization (227, 382). The core DBD contains 
two a-helices: the first one is known as the recognition helix and binds the major 
groove of DNA making contacts with specific bases; the second helix spans the 
COOH terminus of the second zinc finger and forms a right angle with the 
recognition helix (17). The DBD may also contain a nuclear localization and 
nuclear export signals (31, 133). 
The D domain or hinge region of nuclear receptors is variable in length 
and amino acid sequence. Its flexibility can provide DBD rotation along the LBD 
by 180°. This is important for the interaction of receptor dimers with asymmetric 
hormone response elements (HREs) representing direct repeats and HREs 
representing inverted repeats. This region also forms a surface for interaction of 
receptors with coregulators (264) and it may contain a nuclear localization signal 
(310).  
The LBD or the E domain is moderately conserved among members of the 
NR superfamily. It contains an additional transactivation domain, AF-2, which is 
strictly ligand dependent and is a target for interaction with several coactivator 
and corepressor complexes (23, 209, 230). The crystal structure of the LBD has 
been determined for several nuclear receptors and has provided insights 
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regarding the mechanisms involved in lignad binding and transactivation (39). 
The overall structure of the LBD is similar for several NRs and is composed 12 
helices, H1-H12, arranged together in an antiparallel, three-layered sandwich 
which may include two to four β-strands. Helices H1-H11 form the hydrophobic 
lignad-binding pocket whose entrance is guarded by H12 (40, 348). Agonist 
ligand binding induces a conformational change in many NRs resulting in 
alternate positioning of H12. This promotes recruitment of coactivators that 
interact with their short LXXLL-like motifs (where L is leucine and X is any amino 
acid) called NR-boxes. LXXLL-like motifs are present in many coactivators and 
are common motifs required for interacting with the LBD of NRs. The residues of 
the ligand-dependent AF-2 are located in H12 (74, 209). The structural data, 
together with transcriptional activation data, imply that the positioning of helix 12 
is crucial for receptor activation. In addition the LBD also contains nuclear 
localization signals, a dimerization domain, and in some cases, repression 
domains (124, 153, 207). 
The F domain is not found in all receptors and this domain may be 
involved in additional discrimination between receptor agonists and antagonists. 
For example, the F domain of ERα is essential for E2-dependent gene 
transactivation through ERα/Sp1 pathway, but F domain of ERα is not essential 
SERM-mediated activation of ERα/Sp1 in breast cancer cells (163). 
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1.2.3 NR-mediated Transaction 
NRs regulate transcription by binding to specific DNA sequences in target 
genes known as response elements (REs). These elements are located in 
regulatory sequences normally present in the 5’-flanking region of target genes. 
Although REs are often found relatively close to the core promoter, in some 
cases they are present in enhancer regions several kilobases upstream of the 
transcriptional initiation site. The analysis of a large number of naturally occurring 
as well as synthetic REs revealed that a sequence of 6 base pairs of DNA 
sequence constitutes the core recognition motif, also referred to as “half-sites”. 
Although some monomeric receptors bind to a single hexameric motif, most 
receptors bind as homo- or heterodimers to REs composed typically of two core 
hexameric motifs. For dimeric REs, the half-sites can be configured as 
palindromes (Pal), inverted palindromes (IPs), or direct repeats (DRs). Diversity 
among REs is also achieved by the varying number of neutral base pairs 
separating the half-site repeats. This is the key identity factor contributing to the 
binding specificity of different retinoid X receptor (RXR) heterodimer pairs. It 
provides the geometry that is needed for two subunits to interact specifically. The 
insertion of even one extra base pair in the inter-half-site spacing displaces the 
interacting subunits by nearly 3.4 Å and re-orients them by ~35°. This leads to 
the disruption of supportive protein-protein and protein-DNA interactions (268). 
Sequence composition of the spacer nucleotides has been shown to play a less 
critical role in the recognition of REs (268, 386). According to the inter-half-site 
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spacing, these elements are systematic named as shown in Table 1-2. (204, 347, 
386). 
 
Table 1-2 Space rules for nuclear receptor response elements (255). 
Spacer 
NTs 
Systematic 
name 
Acronym Receptor 
Complex 
1 DR1 RARE, PPARE RXR-RXR, 
PPAR-RXR, 
RAR-RXR, …… 
2 DR2 RARE RAR-RXR 
3 DR3 VDRE RXR-VDR 
4 DR4 TRE RXR-TR 
5 DR5 RARE RXR-RAR 
RXR: retinoid X receptor, PPAR: peroxisome proliferator–activated receptor, 
RAR: retinoic acid receptor, VDR: vitamin D receptor, TR: thyroid hormone 
receptor; RARE: retinoic acid receptor response element, PPARE: peroxisome 
proliferator–activated receptor response element, VDRE: vitamin D receptor 
response element, TRE: thyroid hormone receptor response element. 
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The NR superfamily can be broadly divided into four classes based on 
their dimerization and DNA binding properties as shown in Figure 1-5 (205, 322). 
Class I receptors include the known steroid hormone receptors, which function as 
ligand induced homodimers and bind to DNA half-sites organized as inverted 
repeats. Steroid hormone receptors typically bind to palindromes containing 
AGAACA sequence separated by three nucleotides, with the exception of the 
estrogen receptor that recognize the consensus AGGTCA motif with the same 
configuration.  
Class II receptors such as thyroid hormone receptor (TR), retinoic acid 
receptor (RAR), and vitamin D receptor (VDR), heterodimerize with RXR and 
characteristically bind direct repeats. The classic retinoic acid response element 
(RARE) which was found in the RARβ2 gene promoter is a 5 bp-spaced direct 
repeat (DR5) containing the AGTTCA motif. In addition, response elements with 
a DR5 containing the AGGTCA motif also act as RAREs as well as direct 
AGGTCA repeats spaced by 1 bp (DR1) or 2 bp (DR2) (76, 127). RAR-RXR 
heterodimers bind to, and activate transcription from these three RAREs, 
provided target cells express both RARs and RXRs. Only a few natural vitamin D 
response elements (VDREs) are known; several of them contain DR3 elements.
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Studies with “optimized” synthetic response elements assembled from AGGTCA 
motifs have confirmed that DR3 elements bind VDR-RXR heterodimers, and that 
the cognate ligands, vitamin D, and 9C-RA, activate the corresponding promoters 
(78, 122). The thyroid hormone response element (TRE) consensus sequence is 
AGGTCA and TRα binds both AGGTCA and AGGACA motifs (63, 64). TRs have 
a strong preference for DR4, nevertheless, TRs bind other direct repeats 
including DR5, DR2, or DR0 (44, 121). TRs can also bind to inverted palindromes 
with a preferred spacing of six nucleotides (102). 
Class Ill receptors such as hepatocyte nuclear factor 4 (HNF4), chicken 
ovalbumin upstream promoter-transcription factors (COUP-TFs), RXR, Germ-cell 
nuclear factor (GCNF), testicular receptors 2 (TR2), and Tailless homolog (TLX) 
bind primarily to direct repeats as homodimers. Class IV receptors such as 
steroidogenic factor 1 (SF-1), Rev-erb, estrogen-receptor-related receptor (ERR), 
Nerve growth factor induced protein I-B (NGFI-B) and RAR related orphan 
receptor (ROR) typically bind to extended core sites as monomers. Most of the 
orphan receptors fall into class Ill and IV categories.  
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Figure 1-5 Modes of action of NRs (205). 
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1.2.4 Subclasses of Nuclear Receptor by its Ligands 
Lipophilic molecules that bind and activate nuclear receptors are referred 
to generically as “ligands” for nuclear receptors. Unlike polypeptide hormones 
that function via cell surface receptors, ligands for nuclear receptors are not 
directly encoded in the genome. All nuclear receptor ligands are small (molecular 
weight < 1000 daltons [d]) and lipophilic, enabling them to enter cells. Another 
common feature of nuclear receptor ligands is that all are derived from dietary, 
environmental, and metabolic precursors. In this sense, the function of these 
ligands and their receptors is to translate cues from the external and internal 
environments into changes in gene expression. Their critical role in maintaining 
homeostasis in multicellular organisms is highlighted by the fact that nuclear 
receptors are found in all vertebrates as well as insects but not in single-cell 
organisms such as yeast (98). NRs have been divided into three categories 
based on their function and source of ligand (Table 1-3) (3). The "Endocrine" 
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class of NRs binds endocrine-derived ligands and includes the steroid hormone, 
retinoic acid, thyroid hormone, and vitamin D receptors. The "Adopted Orphan 
Receptors" bind dietary lipid-derived ligands and regulate lipid metabolism. 
"Orphan Receptors" are the third category of NRs and the identity of endogenous 
and exogenous ligands for orphan receptors are unknown or poorly defined.  
Ligand-dependent activation of NRs can be variable; however, receptor 
ligands typically induce formation of a DNA-bound homodimer/heterodimer which 
subsequently recruits other nuclear coactivator and coregulatory proteins. This 
complex of nuclear factors associated with NRs is required for association with 
the basal transcription machinery and subsequent activation of gene expression.  
This process is highly complex and may involve different classes of 
coactivators/corepressors and other proteins which modify chromatin structure 
through acetylation or methylation (histone acetyltransferases and 
methyltransferases. We are going to further discuss the mechanisms of 
transcriptional regulation by NRs in the next section.
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Table 1-3 Nuclear receptor ligands and their receptors (3). 
Endocrine 
Endocrine lipld sensors 
Adapted Orphan 
Dietary & endogenous lipid 
sensors 
Orphan 
Endogenous ligands 
uncertain 
GR glucocorticoids 
MR mineralocorticoids 
PR progesterones 
AR androgens 
ER estrogens 
  
RAR retinoic acids 
TR thyroid hormones 
VDR vitamin D, LCA 
 
RXR 9-cis RA, 
DHA 
PPAR fatty acids 
LXR oxysterols 
FXR bile acids 
PAR xenobiotics 
CAR xenobiotics 
 
ERR synthetc steroids 
HNF-4 fatty acids? 
ROR fatty acids, sterols? 
SF-1 phospholipids? 
LRH-1 phospholipids? 
GCNF ? 
PNR ? 
TLX ? 
TR2,4 ? 
NGFI-
B 
? 
COUP
-TF 
? 
RVR ? 
DAX-1 ? 
SHP ? 
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1.3 Mechanism of Transcriptional Regulation by NRs 
1.3.1 Chromatin Structure and Gene Expression 
The genomic DNA in all eukaryotic cells is condensed and packaged by 
histone and nonhistone proteins into a dynamic ordered structure termed 
chromatin. The basic unit of chromatin is the nucleosome which contains 
approximately 146 base pairs (bp) of DNA wrapped in a lefthanded superhelix 
around an octamer of core histone proteins containing two molecules each of the 
following histones: H2A, H2B, H3, and H4 (201). Each core histone has a 
hydrophilic amino-terminal tail containing specific sites for post-translational 
modifications. In addition to core histones, linker histones (H1) can serve to lock 
the incoming and outgoing DNA helix to the outside of the core histone octamer, 
further stabilizing the nucleosome particle as shown in Figure 1-6. 
In the genome, each nucleosome is separated by a stretch of linker DNA 
varying in length from 10 to 60 bp. This form of DNA packaging is considered the 
primary functional unit of chromatin. In vivo, arrays of nucleosomes are packaged 
into canonical ‘30-nm’ fibers and then further condensed into a higher level of 
chromatin structure characterized by 80- to 100-nm chromonema fibers (132). 
Specific nucleosome-nucleosome interactions are essential for the condensation 
of nucleosome arrays into higher ordered chromatin structures (120). The 
packaging of genomic DNA into higher ordered chromatin presents an obstacle 
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for regulated gene expression by presumably restricting access of RNA 
polymerase II and of the basal transcription machinery (131). 
One of the predominant mechanisms used by NRs to activate or repress 
target-gene transcription is the recruitment of coregulatory factors capable of 
covalently modifying the amino terminal ends of histones. These modifications, 
including acetylation and deacetylation, methylation, and in some cases 
phosphorylation, are thought to alter chromatin structure and facilitate the 
subsequent recruitment of other effector proteins. Proteins such as coactivators 
which possess specific enzyme activities such as histone acetyltransferases 
(HATs) and histone/protein methyltransferases (HMTs) are recruited by NRs in 
the presence of cognate ligand where they facilitate activation of target genes. In 
contrast, corepressor complexes containing SMRT NCoR proteins can 
associate with NRs in the absence of ligand, or in the presence of specific 
antagonists, and facilitate transcriptional repression of target genes. Importantly, 
NR corepressor complexes contain HDAC activity that apparently reverses the 
effects of HAT action mediated by NR coactivators. A proposed model for the 
interaction of coactivators and corepressors with NRs is summaried in Figure 1-7.
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Figure 1-6 Structure and assembly of the nucleosome (340) 
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Figure 1-7 Coactivator and corepressor complexes for regulation of nuclear 
receptor-mediated transcription (250).
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1.3.2 NR Mediated Gene Activation 
Transcriptional activation by NRs involves recruitment of distinct classes 
of coactivators and other transcription related factors to promoters in the 
chromatin environment of the nucleus (Fig. 1.7). NRs may use several 
mechanisms to increase transcription of specific NR-dependent genes. First, 
NRs may directly interact with and recruit general transcription factors that are 
components of the preinitiation complex (PIC) to increase the rate of initiation of 
transcription. Second, the receptors may interact with proteins which can alter 
chromatin structure and render the promoter DNA of the target gene more 
accessible to various transcription factors and to RNA polymerase II. Third, the 
receptor may interact with other cellular components that act to bridge 
interactions with members of the PIC to promote formation of a 
transcriptional-active complex. 
1.3.2.1 NR and Transcription Preinitiation Complex (PIC) Formation 
The initiation of mRNA synthesis by RNA pol II involves the direct or 
indirect binding of core promoter DNA elements such as the TATA box, DPE 
(downstream promoter element) and the Inr (initiator) by a collection of “basal” 
transcription factors (TFs) (45, 238). The binding of ligand-activated NRs to DNA 
response elements in the promoter or regulatory regions of a 
hormone-responsive gene stimulates the assembly of a stable basal factor/RNA 
Pol II transcription PIC at the promoter, with recognition of the TATA box and 
     
 40
other core promoter elements by a complex called TFIID (81). The role of 
liganded NRs in promoting the formation of a stable PIC is 2-fold: (i) promoting 
PIC assembly through direct contacts with components of the basal transcription 
machinery (including TFIIB and TFIID) and (ii) recruiting coactivators, which in 
turn facilitate promoter PIC assembly through direct contacts with components of 
the basal transcription machinery and by loosening chromatin structure at the 
promoter (176, 350).  
TFIID is a complex of proteins containing the TATA-binding protein (TBP) 
and a collection of 10 to 12 polypeptides called TBP-associated factors (TAFs) 
(13). The TAFs in the TFIID complex are required for transcriptional activation by 
a number of different DNA-binding activators, including NRs. Several TAFs in 
TFIID, as well as TBP itself, make direct contacts with NRs as a part of the 
transcriptional regulatory process (211). For example, hTAFII30 in TFIID binds to 
ERα, an interaction critical for ERα-dependent transcription. Such interactions 
can help recruit or stabilize binding of TFIID at the promoter, a process that is 
enhanced by the interactions of some TAFs to the core promoter elements (13, 
146). The role of TAFs in NR-dependent transcription is illustrated by the fact that 
TFIID, but not TBP alone, can act synergistically with other cofactor complexes, 
such as Mediator and SWI/SNF, to potentiate transcription by NRs. Together, the 
available data indicate that TAFs are required for full transcriptional activation by 
NRs (13, 202).  
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1.3.2.2 NR Interaction with Coactivators 
Modulation of the assembly of preinitiation complexes by transcription 
factors involves not only direct actions but also indirect actions on components of 
the basal transcriptional machinery. When NRs are bound to their target 
promoters, like other transcription factors, they recruit coregulatory proteins 
termed coactivators or corepressors that activate or inhibit transcription. NR 
coregulators, interact with different NRs domains through their specific 
NR-interacting motifs such as LxxLL or the FxxLF. Many coregulators are most 
likely recruited at the promoter as part of preformed complexes (81, 212). When 
present on target gene promoters, transcriptional coregulators play different roles 
depending on their specific enzymatic activities (e.g., kinase, acetyl- or 
methyltransferase, or ubiquitin- or sumo-ligase activities) or due to their ability to 
recruit other regulatory proteins. Certain coregulators play a crucial role in 
remodeling chromatin structure by modifying histone tails and/or by promoting 
nucleosome remodeling, which in turn facilitates the access of other proteins to 
the promoter. Finally, transcriptional coregulators recruit and stabilize the basal 
transcriptional machinery at the promoter, including RNA polymerase II (pol II), 
leading to the formation of the transcriptional preinitiation and initiation 
complexes as shown in figure 1-7. Since their discovery in the mid-1990s, the 
number of transcriptional coregulators has rapidly increased to more than 150. 
The major group of coactivators enhances NR-dependent transcription by 
modification of the chromatin environment and alleviation of the repressive 
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effects of histone–DNA contacts. Coactivators in this group can be divided into 
two general classes: members of the switch/sucrose nonfermentable (SWI/SNF) 
family of proteins and members of the histone acetyltransferase (HAT) family. 
ATP-dependent Chromatin Remodelers 
The packaging of genomic DNA into nucleosomes restricts the 
receptor-dependent assembly of transcription complexes at the promoters of 
hormone regulated genes. Unlike many DNA-binding transcriptional regulators, 
NRs bind stably and with relatively high affinity to DNA even when their cognate 
HREs are assembled into chromatin (350). Thus, the relevant issue seems to be 
how receptors promote formation of an open chromatin architecture at the 
promoter. One way is through the ligand-dependent recruitment of chromatin 
remodeling complexes, which are multi-polypeptide enzymes categorized by the 
type of ATPase subunit that they contain, including yeast Snf2-like (e.g. 
SWI/SNF) or Drosophila ISWI-like (e.g. RSF, CHRAC, ACF) (223). Human 
SWI/SNF (hSWI/ SNF) represents a family of related complexes usually 
containing eight or nine subunits, with either hBrg1 or hBrm as the ySnf2-related 
ATPase subunit; however, the exact composition of these complexes can vary 
among cell types (164). Chromatin remodeling complexes use the energy stored 
in ATP to mobilize or structurally alter nucleosomes, allowing for greater access 
of the transcriptional machinery to promoter DNA, thus facilitating transcriptional 
activation (164, 278, 350).  
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The involvement of SWI–SNF complexes in NR dependent transcription 
was originally suggested by studies in yeast and mammalian cells which show a 
stimulatory effect of SWI–SNF components on NR-dependent activity (47, 377). 
In addition, cell-based approaches have also supported these results, including 
experiments showing a requirement for hBrg1-receptor interactions in estrogen 
receptor and glucocorticoid receptor gene regulatory activity and chromatin 
immunoprecipitation (ChIP) experiments showed the recruitment of hBrg1 to an 
estrogen-regulated promoter upon hormonal stimulation (84, 109). 
ATP-dependent chromatin remodeling is required for NR-dependent 
transcription but it is not sufficient. Chromatin remodeling may set the stage for 
subsequent actions by coactivators with histone modifying activities, such as 
HATs (82, 192). 
HAT-dependent Chromatin Remodeling 
Histone acetyltransferase coactivators were identified initially on the basis 
of their interaction with the ligand binding domains of a variety of nuclear 
receptors in the presence of cognate receptor ligands, and subsequent studies 
showed these coactivators exhibited HAT activity (318). The most well 
characterized group of HAT coactivators is the p160 family, which contains 
multiple members that share a striking homology. These common structural 
features are represented by steroid receptor coactivator family (SRC-1a) in figure 
1-8A. The SRC (steroid receptor coactivator) family is composed of three distinct 
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but structurally and functionally related members, which are named SRC-1 
(NcoA-1), SRC-2 (TIF2/GRIP1/NcoA-2), and SRC-3 
(p/CIP/RAC3/ACTR/AIB1/TRAM-1), respectively (211). Sequence analysis of 
SRC proteins has identified a basic helix-loop-helix (bHLH) and two Per-Arnt-Sim 
(PAS) domains in the amino-terminal region, a centrally located 
receptor-interacting domain (RID) and a C-terminal transcriptional activation 
domain (AD). The bHLH/PAS domain is highly conserved among the SRC 
members and it serves as a DNA binding and protein dimerization motif for 
interacting with many transcription factors. Detailed analysis revealed three 
conserved LXXLL motifs (NR box) in the RID, which appear to contribute to the 
specificity of coactivator-receptor interactions. HAT activity was identified in the 
C-terminal region of SRC members and there are also activation domains that 
interact with the CREB-binding protein (CBP). Members of the SRC family 
interact with steroid receptors, ER, PR and AR, and enhance their transcriptional 
activation in a ligand-dependent manner (184, 211). 
p300 and CBP are highly related HATs that interact with SRC-1, but also 
bind independently to nuclear hormone receptors in a ligand-dependent manner 
as shown in Figure 1-8 B (54). CREB-binding protein (CBP) was initially 
characterized as a coactivator required for efficient transactivation of 
cAMP-response element-binding protein. p300 was first identified as a 
coactivator of the adenovirus E1A oncoprotein. CBP and p300 share many 
functional properties and protein functions as coactivators for multiple NRs as 
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well as p53 and NF-kB; both possess intrinsic HAT activity and recruit HAT and 
p/CAF (CBP/p300-associated factor) (211). CBP/p300 also interacts with SRC 
family members and synergizes with SRC-1 in transactivation of ER and PR 
(314). This shows that a very large multicomponent HAT complex may be 
assembled in the vicinity of a ligand-bound receptor. 
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Figure 1-8 Functional domains of the p160/SRC family and p300/CBP (340). 
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The link between histone acetylation and transcriptional activation is 
well-established; however, the mechanism of histone acetylation-dependent 
activation of transcription is unclear. Although histone acetylation was initially 
thought to facilitate chromatin remodeling by loosening the association of the 
histone octamer with DNA through the neutralization of positive charges in the 
histone tails, more recent studies suggest that histone acetylation may require 
prior chromatin remodeling or may occur at a post-remodeling step (82, 192, 349). 
The results of one study suggest that post-remodeling histone acetylation by 
p300 may direct the transfer of histone H2A–H2B dimers from nucleosomes to a 
histone chaperone (144). Such an effect may help to establish and maintain an 
open chromatin configuration that favors transcription. The differences observed 
in different experimental systems for the order of chromatin remodeling and HAT 
activity have not been adequately explained, but may represent 
promoter-specific types of regulation (349). Recent results suggest another role 
for histone acetylation, namely to create binding sites on the amino-terminal tails 
of core histones for acetylated lysine binding domains, such as the bromodomain. 
A mechanism like this may allow for the recruitment of bromodomain-containing 
factors (e.g. the HAT TAFII250) to promoters that have nucleosomal histones 
with specific patterns of acetylation (148). Although HAT activity is critical for 
NR-dependent transcription, it is important to note that coactivators such as 
PCAF (233) and p300/CBP contribute other activities to the transcription process. 
For example, p300/CBP interacts with RNA pol II complexes (226) and possess a 
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glutamine-rich C-terminal region similar to the glutamine-rich activation domains 
found in some transcriptional activators, suggesting that p300/CBP may also 
function as classical coactivator by interacting with RNA pol II (175). Furthermore, 
both PCAF and p300/CBP can acetylate nonhistone, transcription-related factors, 
which in many cases alters the activity of those factors (174). For example, the 
acetylation of SRC3 by p300 disrupted the receptor–coactivator complex and 
decreased receptor-mediated gene activation (62). Estrogen receptor alpha is a 
target for p300-mediated acetylation, which may alter the transcriptional activity 
of the receptor (354). Thus some HATs, such as p300/CBP and PCAF, serve as 
multifunctional coactivators for NR-dependent transcription, contributing multiple 
activities to this process. 
HMT-dependent Chromatin Remodeling 
Recent studies indicate that proteins which have HMTs activity are also 
potential coactivators. Two PRMT (protein arginine methyltransferase) family 
members, CARM1 (coactivator-associated arginine methyltransferase) and 
PRMT1, that interact with the carboxyl-terminal region of SRC2 , enhanced 
nuclear receptor mediated transcriptional activation (61, 170). More recent 
studies have shown that the intrinsic methyltransferase activities of CARM1 and 
PRMT1 are required for enhancement activity. CARM1 methylates arginine in the 
tail of histone 3 and functions as a molecular switch that regulates the decision to 
express either genes induced by ligand-activated nuclear receptors or those 
activated by CREB transcription factor (300). CARM1 not only methylates H3 but 
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also an arginine residue in a domain of p300/CBP required for interaction with 
CREB, thus, inactivating the transcriptional activity of CREB. In this regard, 
CARM1 not only functions as a coactivator for nuclear receptor-mediated 
transcription but at the same time acts as a corepressor for CREB-mediated 
transcription (222, 373). 
Mediator Complexes 
Interactions between DNA-bound NRs and the RNA pol II transcriptional 
machinery help to promote formation of stable transcription PICs at the promoter. 
The multiprotein mediator complexes also known as the TRAP and DRIP 
complexes, are another class of NR-and RNA pol II-interacting co-activators. At 
least two individual subunits of Mediator can interact directly with NRs. Med220 
binds to NR ligand-binding domains in a ligand-dependent manner via a receptor 
interaction domain that contains two NR boxes. This subunit is responsible for 
the association of the entire Mediator complex with a variety of NRs in vitro and is 
probably responsible for the recruitment of mediator complex to the promoters of 
NR-regulated genes. For example, Warnmark and co-workers showed that 
TRAP220 interacted preferentially with ERβ compared to ERα and interactions 
were dependent on the two LXXLL NR box motifs (NR1 and NR2) in TRAP220 
(356). However, recently Wu and co-workers in this laboratory showed that in 
ZR-75 breast cancer cells coactivation of ERα by DRIP205 involves multiple 
regions of DRIP205 and ERα, and interaction of these proteins do not require the 
NR box motifs of DRIP205 (368).  
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New coactivators are continually being discovered and these include 
some unexpected molecules such as steroid-receptor-RNA activator-1 (SRA1), 
an RNA transcript, that functions as a eukaryotic transcriptional coactivator for 
steroid hormone receptors (184). An actin-binding protein (mACTN2) not only 
serves as a coactivator for the androgen, estrogen and thyroid hormone 
receptors, but also acts synergistically with GRIP1 to enhance NR-mediated 
(139). In summary, it is clear from coactivator studies that transcriptional 
regulation cannot be considered solely as a chromatin-based process, but should 
be considered as a process that is coupled to many other cellular events that are 
carried out by several distinct groups of proteins and enzymatic activities.  
1.3.3 NR Mediated Gene Repression 
It is now well recognized that gene repression or gene silencing is as 
important as gene activation. Nuclear receptors represent a large family of 
ligand-regulated transcription factors and although DNA binding of steroid 
hormone receptors is ligand-dependent, other nuclear receptors are bound to 
DNA in the absence of their cognate ligand. For example, unliganded NRs such 
as thyroid hormone receptor (TR), retinoic acid receptor (RAR) and most orphan 
receptors are located in nucleus and are bound to their response elements. 
These unliganded DNA-bound receptors actively repress transcription of target 
genes by recruitment of co-repressors. Gene repression by NRs is an important 
and crucial function in vivo since aberrant silencing leads to disease and 
developmental abnormalities. This repression “turns off” target genes and 
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amplifies the magnitude of the subsequent activation by hormone or ligand. For 
example, if the level of gene transcription in the repressed state is 10% of basal 
activity levels in the absence of receptor, a 10-fold hormone-dependent induction 
of this gene above basal levels represents an overall 100-fold increase in 
expression compared to the repressed genes (136).   
The ligand-dependent switch between the repressed and activated 
receptor conformations explains how hormones activate gene expression. 
However, many hormone-repressive target genes can be down-regulated by 
receptors after treatment with hormone. This is referred to as ligand-dependent 
negative regulation of transcription, or transrepression, and is different from the 
repression of basal transcription by unliganded receptors. The mechanism of 
negative regulation is not well understood. One mechanism involves nuclear 
receptor binding to DNA binding sites that reverse the paradigm of 
ligand-dependent activation (negative response elements), where the 
ligand-bound receptors recruit corepressors and HDAC activity to these binding 
sites (296). 
1.3.3.1 NR Interaction with Corepressors 
Various corepressors for NRs have also been identified. Corepressors 
such as silencing mediator of retinoid and thyroid hormone receptors (SMRT), 
nuclear receptor corepressor (NCoR) interact with NRs in a ligand-dependent 
manner and ligand binding leads to their dissociation from the receptors. 
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However, some corepressors such as LcoR (ligand-dependent nuclear-receptor 
corepressor), RIP140 (receptor-interacting protein-140) and REA (repressor of 
estrogen receptor activity) (77, 365), bind nuclear receptors in a 
ligand-dependent manner and competitively displace coactivators. These 
observations indicate the existence of specific regulatory mechanisms that use 
similar, but reverse, approaches for attenuating the function of agonist-bound 
receptors. 
SMRT, NCoR  
The SMRT and NCoR are related transcriptional corepressors isolated by 
virtue of their interaction with RAR and TR (65, 130). SMRT and NCoR bind 
unliganded TR or RAR, and their interactions are disrupted after binding of TR or 
RAR to their respective ligands. Subsequent studies show that SMRT and NCoR 
also interact with other NRs, including VDR, PPARδ, and LXR, and with orphan 
NRs, such as Rev-ErbA, COUP-TF, RORα, and DAX (212). SMRT or NCoR also 
interact with steroid hormone receptors, including ER, AR, and PR (86, 193), and 
this only takes place when steroid hormone receptors bind their corresponding 
antagonists. For example, tamoxifen, a known ER antagonist/agonist used for 
breast cancer treatment, enhances interactions between ER and NCoR. The 
interaction between SMRT or NCoR and NRs is dictated by two NR-interacting 
motifs located at the C-terminal ends of both proteins, with a consensus 
sequence of L IXXI VI, named the CoRNR motif (135). Sequence comparison 
of SMRT and NCoR indicates that they share a conserved domain called the 
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SANT domain (4). The N-terminal SANT domain of SMRT and NCoR is involved 
in associating with histone deacetylase 3 (HDAC3) and is required for activating 
its deacetylase activity (116, 383). The SANT domain is involved in histone 
binding. This observation was later confirmed by a study on the SANT2 domain 
of SMRT (378) which showed that the SANT2 domain can directly bind histones. 
Interestingly, SANT2 of SMRT prefers to bind unacetylated histones over 
acetylated forms; however, this property was not observed for the SANT1 
domain of SMRT, indicating that each of these two SANT domains encodes 
distinctive properties. The preferential binding of the SMRT SANT2 domain to 
unacetylated histone tails suggests that it can block the binding of HATs to 
histones and it appears that the two SANT domains of SMRT and NCoR can 
synergize with each other to promote and maintain histone deacetylation.  
Both SMRT and NCoR complexes are estimated to be 1.5–3 MDa in size 
(117, 191), suggesting that SMRT and NCoR associate with multiple protein 
components. Biochemical purification and characterization of these SMRT and 
NCoR associating proteins have identified HDAC3, transducing beta-like protein 
1 (TBL1), and TBL1 related protein (TBLR1) as common components (117, 191, 
378). Further characterization of TBL1 and TBLR1, which are related WD40 
repeat proteins, has revealed their selective affinity for histones H2B and H4 
(378), and this histone-binding activity is important for their transcriptional 
repression activity. These results reveal that TBL, TBLR1, and HDAC3 are 
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integral components of the SMRT and NCoR complexes and are critical for the 
transcriptional repression of NRs.  
RIP140 and LCoR 
Although agonist binding to NRs is primarily associated with recruitment of 
coactivators, recent studies show that agonist binding also results in binding of 
corepressor such as RIP140 and LCoR (52, 104). RIP140 was first identified by 
its interaction with TR, RAR, RXR, and PPAR as a corepressor in a 
ligand-dependent manner by using the GAL4 reporter system (186, 339). 
Interactions between RIP140 and NRs is mediated through a unique motif at the 
C-terminal region of the protein (148), although the constitutive binding appears 
to be mediated through repeated LXXLL motifs (101). Mutations in the 
NR-interacting motif in RIP140 decrease its ability to suppress an RA-responsive 
reporter gene, suggesting that RIP140 indeed functions as an NR corepressor. 
Moreover, RIP140 suppresses RA receptor-mediated induction by RA in a 
dose-dependent manner (148). Transcriptional repression by RIP140 has also 
been attributed to its interaction with HDAC1, HDAC3, and CtBP (352, 364).  
LCoR is another NR corepressor that was first isolated as a 
ligand-dependent interacting factor of ERα LBD in a yeast two-hybrid screening 
(104). Interactions of LCoR with ER in yeast and in mammalian cell lines takes 
place in an E2-dependent manner and there is evidence that LCoR interacts with 
other nuclear receptors, including GR, PR, and VDR, in a ligand 
binding-dependent fashion. Furthermore, LCoR also interacts selectively with 
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HDAC3 and HDAC6 but not with HDAC1 or HDAC4. The interactions between 
RIP140 or LCoR and NRs are mediated through motifs similar to the LXXLL motif 
and it has been postulated that in addition to the active role of RIP140 and LCoR 
as gene repressors, they also compete with coactivators for binding the 
hydrophobic pocket in the LBD. This competitive property of RIP140 and LCoR is 
ligand-dependent. The combination of both properties could be the key reason 
for the rapid attenuation of transcription immediately after agonist-induced 
transactivation.  
1.3.4 From Repression to Activation 
The possibility of switching gene expression from ‘off’ to ‘on’ and vice 
versa in mammalian system includes several regulatory strategies that cooperate 
to impose precise control of gene expression. 
1.3.4.1 Allosteric Regulation of NR Activity 
Ligand binding is the crucial molecular event that switches the function of 
nuclear receptors from active repression to transcriptional activation for the 
heterodimeric receptors such as RAR or TR that are constitutively bound to DNA. 
The hormone binding induces a conformational change in the ligand-binding 
domain of the receptor, which results in reduced affinity for corepressors and, 
enhanced affinity for coactivators. Similarly, agonist binding to steroid receptors, 
such as ER, progesterone receptor (PR), GR or AR, also induces a specific 
conformation that favors coactivator binding, whereas antagonist binding 
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promotes the interaction with corepressors. However, some recent studies show 
that there are additional molecular events that also modulate the nuclear receptor 
switch from repression to activation.  
1.3.4.2 Turnover and Transcription 
The degradation of transcriptional activators such as NRs is often required 
for gene activation. The cyclic turnover of some NRs on regulated promoters 
correlates with proteasome-dependent degradation activity, chaperone activity 
and chromatin remodeling events (108, 225, 276). The significance of an 
association between transcriptional activation and proteolysis of the activator is 
unclear and is somehow counterintuitive, since one might expect the removal of 
activators to correlate with the negative control of gene transcription. However, 
the cyclic clearance of nuclear receptors may be crucial, because it allows a 
continuous reassessment of the ‘state of the cell’ — each cycle would overcome 
the default of transcriptional repression only if the activating stimulus was still 
present (291). However, there are also examples where proteasome inhibition is 
reported to enhance transcriptional activation, and this indicates that the role of 
protein degradation in transcriptional regulation could be cell, nuclear-receptor 
and even promoter specific (37, 100). 
Reid et al. have reported that proteasome-mediated degradation and 
hERα-mediated transactivation are inherently linked and act to continuously turn 
over hERα on responsive promoters (276). In contrast, Fan et al. showed that the 
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proteasome-dependent degradation is not essential for ER transcriptional activity 
(100). In HeLa cells transfected with ERα, blocking either ubiquitination or 
proteasomal degradation markedly increased E2-induced expression of an 
ER-responsive reporter. In MCF-7 breast cancer cells, proteasome inhibition 
enhanced E2-induced expression of pS2 and cathepsin D, but decreased 
progesterone receptor (PR) expression. The results further indicate that promoter 
context must be considered when evaluating the relationship between ERα 
transcription and proteasome inhibition. In addition to ER, PPARα, GR, RARγ, 
RXRα, and TR are also regulated by the ubiquitin–proteasome system (38, 80). 
Ubiquitination of PPARα was decreased in the presence of ligand, providing a 
mechanism for the ligand-dependent stabilization (32).  
Recruitment of the ubiquitylation machinery and proteasome-dependent 
degradation of the coregulators is also required for transcriptional activation. In 
the case of the NCoR-containing corepressor complex, the 26S proteasome 
components are involved in promoting the release of the corepressors in 
response to ligand binding (249). TBL1 and TBLR1, two NCoEx (nuclear 
corepressor exchange factors) factors, are components of the NCoR and SMRT 
corepressor complexes and are required for the repression of specific 
transcription units (191, 335). TBL1/TBLR1 also serve as specific adaptors for 
the recruitment of the ubiquitin conjugating/20S proteasome complex to mediate 
exchange of NR corepressors for coactivators upon ligand binding. This implies 
that signals that promote gene induction must turn on parallel pathways to 
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activate the exchange machinery and release the repression checkpoint. 
Therefore, activation of the NCoEx factors could represent a control, which is 
imposed to maintain more robust transcriptional repression and to avoid 
undesirable gene expression. This level of regulation would increase the 
amplitude of transcriptional activation events by imposing a repression 
checkpoint. Furthermore, periodic cycles of NRs are important for continuous 
assessment of the hormonal state of the cell, then re-establishment of a 
repression checkpoint at each clearance phase could also provide a tighter 
control on gene activation. This means that the ubiquitylation and the release of 
the corepressors would be crucial, not only during the first activation step, but at 
each cycle of receptor assembly on the promoter.  
1.3.4.3 Nuclear Integration of Signaling Pathways 
NRs respond not only to hormonal stimulation, but they can also integrate 
information derived from a large variety of external stimuli. Several signaling 
pathways activated by various developmental or physiological signals exhibit 
crosstalk with nuclear receptor-mediated responses through both direct and 
indirect mechanisms. The transcriptional activity of nuclear receptors is 
modulated by the induction of post-translational modification of the receptor itself 
or of its coregulatory proteins. Phosphorylation, acetylation, sumoylation, 
ubiquitylation and methylation are among the modifications that modulate the 
functions of nuclear receptors and that potentially constitute an important cellular 
integration mechanism. It has been suggested that these modifications influence 
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cellular localization, enzymatic activity and stability of targeted proteins, and 
could also be important in modulating the timing of sequential recruitment of the 
different classes of coregulators to a single transcription unit. The transcriptional 
coactivators CBP and p300 are involved in numerous transcriptional events 
mediated by different trans-acting transcription factors. Both CBP and p300 are 
phosphoproteins and their phosphorylation status is under cell-cycle control 
(374). For example, p300 is phosphorylated by CDC2 and CDK2 kinases and 
negatively regulated by cyclin E–CDK2 (22). An interesting possibility is that the 
enzymatic activities of CBP and p300 are directly modulated as a result of the 
phosphorylation events that occur during cell-cycle progression. This was 
suggested by Ait-Si-Ali et al., who reported that general HAT activity peaked 
during the G1/S transition, and that the HAT activity of CBP was enhanced by the 
C-terminal phosphorylation mediated by cyclin E–CDK2 (12, 165). 
Other kinases, which include PKA, Ca2+/calmodulin-dependent kinase IV 
(CaMKIV) and MAPK, phosphorylate different CBP residues, thereby enhancing 
its transcriptional-activation activity (59, 147, 372). For example, phosphorylation 
by p44 MAPK has a positive effect on the enzymatic activity of CBP (11). In 
contrast, p300 phosphorylation by PKC represses transcriptional activity (379), 
which is consistent with the opposing activities of CBP and p300 on proliferation 
and the response to DNA damage. 
Phosphorylation is not the only modification that is used to integrate 
signalling pathways and coactivator functions. For example, CARM1-dependent 
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methylation of a specific domain of CBP (the KIX domain) which interacts with 
the kinase-interacting domain (KID) of CREB, is important for inducing the 
dissociation of CBP from CREB, and for inhibiting CREB-dependent 
transcriptional activation (373). Furthermore, p300 is also ubiquitinated and 
degraded by the ubiquitin–proteasome pathway during F9 embryonal carcinoma 
cell differentiation. Interestingly, p300 shows different phosphorylation patterns in 
undifferentiated versus differentiated cells, and the changes in phosphorylation 
status that are promoted by PKA affect its HAT activity only during differentiation 
(42, 145). 
Post-translational modifications of corepressors have also been reported. 
A recent paper showed that the direct phosphorylation of SMRT by IKKα is 
required for NF-κB mediated transcription (126). The phosphorylation on SMRT 
resulted in the dissociation from HDAC3 and nuclear export of SMRT. Failure of 
IKKα to stimulate this response inhibits the recruitment of NF-κB to promoters, 
blocking transcription and sensitizing cells to apoptosis (249). This is consistent 
with the observation that the ubiquitin-dependent dismissal and degradation of 
corepressors is required for the switch from gene repression to gene activation 
by nuclear receptors. Furthermore several kinases, including MAPKs, 
AKT/protein kinase B and casein kinase-2, modify NCoR and SMRT and to 
induce their relocalization from the nucleus to the cytoplasm (19, 129, 150). 
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1.4 Mechanism of ER Mediated Transcription Activity 
1.4.1 Introduction  
Estrogens are steroid hormones that regulate growth, differentiation, and 
function in a broad range of target tissues in the human body. The most potent 
and dominant estrogen in humans is 17ß-estradiol, but lower levels of estrone 
and estriol are also present. The biological effects of estrogens as shown in 
Figure 1-9 are mediated through ER α and ß, which are members of a large 
superfamily of nuclear receptors. These receptors act as ligand-activated 
transcription factors. The classical genomic mechanism of ER action involves 
estrogen binding to receptors in the nucleus, after which the receptors dimerize 
and bind to specific response elements known as estrogen responsive elements 
(EREs) located in the promoters of target genes (229). However, around one 
third of ER regulated genes in humans that do not contain ERE-like sequences 
(232), and the molecular mechanisms of transcriptional regulation by ER at 
alternative response elements are being extensively investigated. E2 induced 
transactivation of some genes involved ER-protein interactions where ER does 
not directly bind DNA but activates another DNA-bound transcription factor (113). 
This mechanism can be referred to as non-classical genomic pathway. 
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Figure 1-9 Models of estrogen action (125) 
 
     
 62
There are rapid biochemical and physiological responses that occur within 
seconds or minutes after estrogen administration that cannot be accounted for by 
changes in gene expression mediated by nuclear ER. These are known 
non-genomic actions of E2 and are believed to be mediated through 
membrane-associated ER. Non-genomic pathways are associated with activation 
of various protein-kinase cascades which indirectly influence gene expression, 
through phosphorylation of other transcription factors such as AP-1, serum 
response factor (SRF), and Elk-1 (75, 88, 154, 173).  
1.4.2 Overview of Estrogen Receptor Structure 
The biological effects of E2 are mediated by the ER and until 1996 it was 
assumed that a single ER was responsible for mediating the effects of E2, 
anti-estrogens and other selective ER modulators (SERMs). However, a second 
ER, designated as ERβ, has been identified (the former ER is called ERα). And 
this has initiated an extensive reevaluation of the comparative functions of ERα 
and ERβ in normal physiology and in diseases including cancer (179). 
ERα and ERβ are encoded by separate genes and belong to the 
steroid/thyroid hormone superfamily of nuclear receptors (118). The structures of 
the two ERs are compared in Figure 1-10. 
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Figure 1-10 The structure homology between ERα and ERβ (171) 
 
Like other NRs, both ER subtypes consist of six defined structural 
domains. There is considerable variability in the A/B, hinge (D), and F domains of 
ERα and ERβ. However, the DNA binding domains (DBDs) of ERα and ERβ are 
highly homologous (97) and thus ERα and ERβ bind various EREs with similar 
affinities. The ligand-binding domain (LBD) of ERα and ERβ also share a high 
degree of homology and it is not surprising that many compounds bind both 
receptors with similar affinities (178) or have similar potencies in activation of 
ERE-reporter gene expression (24). However, the two receptors have distinctly 
different tissue distribution and levels in normal tissues and in tumors (71, 190). 
These data together with the different phenotypes of the ERα and ERβ knock-out 
mice support the idea that the two ERs are not merely redundant but have 
distinct roles in estrogen and SERMs signaling (33).  
The ER contains two distinct transcriptional activation domains; activation 
function 1 (AF1) at the N-terminal and activation function 2 (AF2) at the carboxy 
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terminal. The N-terminal A/B domain is the least conserved region with only 17% 
identity between human ERα and ERβ (97). The N-terminal domain encodes a 
ligand-independent transactivation function (AF1) a region involved in 
protein-protein interactions and transcriptional activation of target gene 
expression. AF1 interacts with multiple proteins, including the p160 steroid 
receptor coactivator-1 (SRC1) and p300 (210, 236), general transcription factor 
TBP (362) and other coactivator proteins such as p68 RNA helicase (96), 
MMS19 (369) and RNA coactivator SRA (357). AF1 is also responsible for 
ligand-independent activation of ER through several different kinase signaling 
pathways (168). Serine 118 is the target for mitogen-activated protein kinase 
(MAPK)-dependent phosphorylation in response to growth factors (14, 149). 
Serines 104 and 106 are phosphorylated by the cyclin A-CDK2 complex (279).  
The ER LBD is a wedge–shaped structure that consists of 12 α helices. 
The LBD forms the pocket for ligand binding, homo-and hetero-dimerzation and a 
binding surface for coactivators and corepressors. The ligand-binding pocket is 
guarded by helix-12 (H12), which forms a movable lid over the pocket and 
contains residues that are crucial for AF2 function. Crystallographic analysis of 
the ERα LBD has established that ligand binding has a dramatic effect on 
receptor structure. Agonists such as 17ß-estradiol and diethylstilbestrol induce a 
receptor conformation in which the H12 is aligned over the hormone binding 
cavity, resulting in the formation of a specific binding site for coactivators (43, 
305). Coactivators recruited to the AF2 of ERα contain a distinctive common 
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signature motif termed an NR-box, comprising the core consensus sequence 
LXXLL where L is leucine and X is any amino acid. This interaction site on ERα is 
a shallow, hydrophobic groove that is formed by residues from H3, H4, H5 and 
H12. The LXXLL motif functions as a hydrophobic docking module in a helical 
conformation and all the three leucines of the motif make contacts with the 
groove which is stabilized by a charge clamp. Introduction of mutations in either 
partner abrogates the interactions (305). The agonist-induced conformational 
change of the LBD is also necessary for the nuclear receptor transactivation 
function.  
SERMs such as raloxifene and tamoxifen, bind across the cavity in a 
similar manner to agonists. However, their bulky side chains cannot be fully 
accommodated within the binding cavity. Instead, the side chains protrude from 
the binding cavity, resulting in the displacement of H12. This repositioning of H12 
in the LBD disrupts interactions between the hydrophobic grooves in the LBD 
with coactivators (43, 305).  
The crystal structures of ERβ isoform bound to genistein, a partial agonist 
for ERβ, and raloxifene, a pure antagonist for ERβ, have also been determined 
(257). Genistein, an isoflavonoid phytoestrogen, displays 7-30 fold higher affinity 
for ER β over ERα. The orientation of H12 in genistein–bound ERβ LBD is in a 
partially occupied antagonistic position compared to an agonist, and this explains 
the partial agonistic activity of genistein. However, in raloxifene-bound to the LBD 
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of ERβ, the piperidine ring of the ligand protrudes from the cavity and prevents 
H12 from adopting its agonist position. This feature is responsible for pure 
antagonistic properties of raloxifene on ERβ. The structure of the ERß LBD 
complexed with a pure antagonist, ICI 164,384, has been determined; and shows 
that binding of this antagonist completely destabilizes H12 and prevents it from 
adopting either agonist or SERM orientation (258). 
1.4.3 Membrane-associated ER  
The existence and function of membrane-associated ER (mER) was first 
reported in 1977 (256) and over the last 10 years there has been renewed 
interest on the structure and function of mER. There is evidence showing that the 
membrane and nuclear receptors are the same protein and this is based on 
immunohistochemistry staining of membrane ER, using a panel of antibodies 
directed against multiple epitopes of the nuclear ER (241). In addition, 
GH3/B6/F10 rat pituitary tumor cells transfected with an antisense oligonucleotide 
to nuclear ER resulted in loss of mER (231). Also in ER-negative Chinese 
hamster ovary (CHO) cells, transfection with cDNAs of ERα or ERß resulted in a 
single transcript, specific binding activity of labeled E2, and expression of ER in 
both nuclear and membrane fractions (272). However, the definitive proof that 
endogenous membrane and nuclear ER are the same protein which requires 
separate isolation and sequencing of the two receptor pools has not been carried 
out. In contrast to most membrane receptors, ER has no intrinsic transmembrane 
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domain, and there is evidence that a third party protein such as Shc, p85α of 
phosphatidylinositol 3-kinase (PI3K), caveolin and insulin-like growth factor-1 
receptor (IGF-1R) maybe required for linking the cytoplasmic ER pool to the inner 
face of the plasma membrane (218, 271, 316).  
Shc, an adapter protein, has no intrinsic kinase domain and mainly 
transduces signals dependent on protein–protein interactions (269). Three 
domains on Shc mediating protein–protein interactions are the phosphotyrosine 
binding (PTB) domain in the amino-terminal region, the Src homology 2 (SH2) 
domain in the carboxy-terminal region and a proline rich region called the 
collagen homology (CH) domain (246). When a receptor like IGF-1R is activated, 
Shc binds rapidly to IGF-1R through its PTB domains, leading to Shc itself being 
phosphorylated by receptor tyrosine kinase (247). The phosphorylated tyrosine 
residues on the PTB domain of Shc provide the docking sites for binding the SH2 
domain of Grb2 (Growth factor receptor binding 2) and this complex recruits SoS 
(Son of Sevenless), a guanine nucleotide exchange protein (282), leading to 
activation of the Ras/Raf/MAPK pathway (35, 247). It has been reported that E2 
rapidly induced Shc phosphorylation as well as Shc interaction with ERα in 
MCF-7 and long-term estrogen-deprived (LTED) MCF-7 cells. The N-terminal 
A/B domain of ERα was required and sufficient for interactions with the PTB and 
SH2 domains of Shc, although the full-length receptor was required for 
E2-mediated response in MCF-7 cells (317). Recently it is also shown that Shc, 
ERα and IGF-1R form a ternary complex in MCF-7 cells and down-regulation of 
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any of these proteins by small inhibitor RNAs (siRNAs) abrogates E2-induced 
activation of the MAPK pathway (316). These data suggested that Shc serves as 
a translocator for ERα by binding to the receptor and then carrying it to the 
Shc-binding sites of IGF1-R that are located on the cell membrane and transduce 
estrogen signals for activation of MAPK pathway. 
The p85α subunit of PI3K is also an adapter protein. The p85α contains an 
N-terminal SH3 and a C-terminal SH2 domain separated by an N-terminal SH2 
domain (183). p85α can associate with IGF-1R directly or indirectly by binding 
IRS-1, a substrate of IGF-1R (16, 376), leading to the activation of the p110 
catalytic subunit. It has been reported that ERα but not ERβ interacts directly with 
the P85α, and this association is required for E2-induced activation of PI3K 
pathway in endothelial and breast cancer cells (50, 311). Recently, the adaptor 
protein p130Cas was shown to transiently interact with ERα in a multi-molecular 
complex containing the c-Src kinase and the p85α in T47D breast cancer cells 
(46). Transient overexpression of p130Cas in T47D cells increases 
E2-dependent Src kinase and ERK1/2 MAPK activities. Furthermore, 
downregulation of p130Cas by siRNA was sufficient to inhibit E2-induced ERK1/2 
MAPK activity and cyclin D1 induction, suggesting that the adaptor protein 
p130Cas associates with the ERα transducing complex, regulating E2-dependent 
activation of c-Src kinase and downstream signaling pathways. 
The cellular tyrosine kinase c-Src is involved in intracellular signaling and 
cell proliferation initiated by both growth factors and steroids. Several reports 
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have shown that c-Src kinase activity is required for E2-induced stimulation of 
MAPK and PI3K activity in breast cancer and bone cells (46, 50, 317). 
Microinjection of kinase-dead c-Src into breast cancer cells (MCF-7 and T47D) 
prevented stimulation of cell proliferation by either E2 or progestins (48). In 
addition, the essential role for c-Src in E2-dependent activation of MAPK 
pathway was supported in studies using embryonic fibroblasts derived from Src-/- 
mice, which failed to support rapid activation of the MAPK pathway in response 
to E2, whereas wild-type c-Src+/+ cells did (172). ERα has been shown to 
interact with the SH2-domain of c-Src (21, 36, 218), and the phosphorylated 
tyrosine at position 537 in the LBD of ERα is required for this interaction (25). It 
has also been reported that moderator of nongenomic activity of ER (MNAR) 
which is identified from a breast cancer cell library (367) mediated or stabilized 
the interactions between ER and c-Src. MNAR associates with ligand-bound ERα 
and ERβ through LXXLL motifs, and binds to the c-Src SH3 domain via a 
proline-rich region (25). It is suggested that MNAR brings the ER into proximity 
with c-Src and helps enhance activation of c-Src by providing more effective 
interaction of ER and c-Src relieving c-Src inhibition through binding to the SH3 
domain. 
In endothelial cells, as in other cell types, ER has been found in caveolae 
where they activate endothelial nitric oxide synthase (eNOS) through protein 
kinase-mediated phosphorylation (56, 57). Caveolae are specialized membrane 
invaginations enriched in the scaffold protein caveolin-1. Caveolae facilitate 
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signal transduction by providing a subcellular location for various signaling 
molecules (302). It has been reported that Serine 522 of ERα is necessary for the 
physical interactions with N-terminal scaffolding domain of caveolin-1 protein 
(270). Marino and colleagues (6, 7) have shown that cysteine 447 a residue 
which is crucial to steroid-independent palmitoylation of the receptor is also 
important for association with the caveolin-1. Mutation of this single amino acid or 
inhibition of palmitoylation with 2-bromo-palmitate results in a significantly 
decreased expression of membrane receptors, compared to wild-type ER 
expression. Furthermore, cysteine 447-mutated ERα does not support 
E2-induced proliferative signaling through ERK and PI3K (6).  
Some motifs in the E domain of ERα are also critical for membrane 
localization and function and this includes residues necessary for dimerization of 
the endogenous membrane ERα and ERβ (55, 275). Mutation of these motifs 
prevents both receptor dimerization and E2-dependent signaling through ERK, 
PI3K, and cAMP in breast cancer cells (275). In contrast, eNOS activation in 
COS cells transfected with ER may not require membrane ER dimerization (55). 
Very recently, it was reported that elements within the nuclear localization 
sequence (NLS) of ERα (D domain) were required for E2-induced activation of 
ERK and PI3K and nitric oxide production through eNOS activation in transfected 
COS cells (385). 
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1.4.4 Genomic ER Activity  
1.4.4.1 Classical Genomic ER Activity 
 The classical mechanism of ER action involves estrogen binding to 
receptors in the nucleus, after which the receptors dimerize and bind to specific 
response elements known as estrogen response elements (EREs; 
GGTCANNNTGACC) located in the promoters of target genes as shown in 
Figure 1-11 (229). This consensus sequence was first identified in the 
vitellogenin genes from xenopus and chicken (166). Hormone binding also 
induces a conformational change within the ligand binding domain of ER, and this 
conformational change allows coactivator proteins to be recruited (280). This 
leads to alteration of chromatin, histone unwinding, interactions with components 
of the basal transcription machinery complex, and subsequent mRNA 
expression. 
1.4.4.2 Non-Classical Genomic ER Activity 
A number of studies have shown that ER can regulate transcription without 
binding directly to DNA. The receptors in such cases are tethered through 
protein-protein interactions to a transcription factor complex that contacts the 
DNA as shown in Figure 1-11. Through this mechanism, ER regulates 
expression of a large number of estrogen-responsive genes that do not contain 
EREs. This mechanism is also used by other members of the nuclear receptor 
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Figure 1-11 Genomic and nongenomic actions of ER on a target gene promoter 
(30). 
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 superfamily and is often referred to as transcriptional cross talk (113). ER/AP-1 
and ER/Sp1 are two major pathways of ER nonclassical genomic actions.  
ER/AP-1 Pathway 
An E2-responsive AP-1 element was initially identified in the proximal 
promoter of the ovalbumin gene (336) and other E2-responsive AP-1 elements 
have been identified in the collagenase, insulin-like growth factor 1, quinone 
reductase, and cyclin D1 gene promoters (111, 345, 346). Fos and Jun family 
proteins bind AP-1 elements as homo-or heterodimers. These proteins contain 
leucine zipper domain that mediates DNA binding and are typically associated 
with genes that rapidly responsed to various extracellular stimuli (303).  
Mechanistic studies of ER/AP-1 actions have shown that the requirement 
for ER structural domains is dependent on the receptor subtype and on ligand 
structure. For example, E2-dependent activation of ERα/AP-1 complexes 
requires the AF-2 domain of the receptor, which binds p160 coactivators and 
stabilizes formation of a multiprotein complex containing c-Jun, ERα, and 
transcriptional coactivators at the promoter. However, the ER DBD is required for 
tamoxifen-activated ERα/AP-1 dependent activity (361). Furthermore, ICI, 
182,780, an inhibitor of ER dimerization and ERE binding, activates an AP-1 
reporter construct (254). Interestingly, full length ERα containing mutations in 
AF1 also compromised E2-mediated AP-1 activity, indicating that ERα/AP-1 
action requires both AF1 and AF2 (363).  
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ERβ also activates transcription from an AP-1 element. However, the 
effects of estrogen and antiestrogen on ERβ/AP-1 contrasts to those observed 
for ERα/AP-1. E2, ICI, 182,780, tamoxifen, and raloxifene all activate an AP-1 
reporter construct in cells cotransfected with ERα whereas, in the presence of 
ERβ, E2 not only acts as antagonist but also inhibits the activity of tamoxifen and 
raloxifene dependent induction of ERβ/AP-1. However, either tamoxifen or 
raloxifene alone behave as full agonists (240). 
ER/Sp1 Pathway 
E2-responsive GC-rich elements were initially identified in the c-myc gene 
promoter (91). This site contains a nonconsensus ERE-half site (ERE½) and a 
Sp1 binding site that was required for estrogen-mediated induction. Similar 
ERE½/Sp1 elements have been subsequently characterized in the cathepsin D 
(177), heat shock protein 27 (Hsp27) (262), TGFα (353), prothymosin α (208), 
and human PR A (253), gene promoters. However, mutation of the ERE1/2 in the 
Hsp27 promoter did not result in the loss of E2 responsiveness, and the 
E2-dependent ERα/Sp1 action is still observed in cells transfected with a DBD 
deletion ERα mutant. The data suggested that GC-rich site alone was sufficient 
for E2-responsiveness and ERα binding to DNA was not required. The 
ERE-independent ERα/Sp1 action has also been observed for several genes 
including retinoic acid receptor α (327), c-Fos (87), insulin-like growth 
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factor-binding protein-4 (266), bcl-2 (85), adenosine deaminase (371), 
thymidylate synthase (370), cyclin D1 (51), cad (161), E2F-1 (228). 
Although both ERα and ERβ form complexes with Sp1 protein, only ERα 
induces consensus Sp1 element-linked reporter gene activity whereas ERβ, 
exhibits minimal or decreased the basal reporter gene activity and these 
responses are ligand- and cell type-specific. Interestingly, it was recently 
reported that both ERα and ERβ regulate EGF receptor gene expression through 
GC-rich elements and, depending on ligand, ERβ exerts full agonist activity on 
this promoter, indicating that promoter context is also an important factor in 
ERβ/Sp1 action (292). 
ERα/Sp1 protein-protein interactions were investigated in vitro using GST 
pull-down assays, which showed interaction between the C-terminal end of Sp1 
and multiple regions of ERα (261). Additionally, it has been shown using a series 
of ERα deletion mutants and ERα/ERβ chimeric mutants that the AF1 domain of 
ERα is critical for ERα/Sp1-mediated transactivation. Recent studies indicated 
that E2-dependent activation of ERα/Sp1 also required the C-terminal F domain 
of ERα, which was not required for antiestrogen activation of ERα/Sp1 and 
overexpression of a C-terminal F domain peptide (aa 575-595) specifically 
blocked E2-mediated ERα/Sp1 transactivation, suggesting that other nuclear 
cofactors interacting with the F domain may be important for ERα/Sp1 action 
(163).    
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ERα not only interacts with Sp1 but also with Sp3 protein, another 
member of Sp protein family that can also act as transcriptional repressor. It was 
reported that vascular endothelial growth factor (VEGF) gene expression is 
regulated by ERα/Sp1 or ERα/Sp3 either positively or negatively and Sp1/Sp3 
ratios maybe critical for VEGF gene regulation. By using Sp protein deficient SL2 
cells, upregulation of the VEGF promoter activity with E2 treatment was observed 
in cells cotransfected with ERα and Sp1 expression plasmid whereas 
downregulation of the same promoter activity was observed when cells were 
cotransfected with ERα and Sp3 expression plasmid (320, 321). 
1.4.5 Nongenomic ER Activity  
Evidence is accumulating that estrogens exert nongenomic actions that 
are too rapid to be accounted for by the activation of RNA and protein synthesis. 
Nongenomic actions are a common property of steroid hormones and are 
frequently associated with the activation of various protein-kinase cascades 
(198).  
The nongenomic mechanism of estrogen action can be grouped into two 
types as shown in Figure 1-9 and 1-11. First, some models propose that the rapid 
membrane events are mediated by the classical ERα, which initiates signaling 
cascades by associating with membrane structures including G proteins, 
caveolins, and receptor tyrosine kinases. In the second type of model, the ERα is 
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not involved and another membrane-associated estrogen-binding protein is 
believed to mediate the response to estrogen. 
1.4.5.1 ER-mediated Nongenomic Action 
Mitogen Activated Protein Kinase (MAPK) 
Mitogen activated protein kinases (MAPKs) are important enzymes in 
signal transduction and are highly conserved among eukaryotes. In mammalian 
cells, MAPKs include the extracellular signal-regulated kinase (ERK) 1/2, the p38 
kinase and the stress-activated protein kinase (SAPK) or c-Jun NH2-terminal 
kinase (JNK) cascades (58, 245). ERK primarily responds to mitogenic signals, 
while JNK and p38 are predominantly activated by stress signals. 
Although MAPKs are a diverse group of kinases, they share an 
evolutionarily conserved model of activation, which consists of the sequential 
phosphorylation of three kinases. The MAPK kinase kinase (MAPKKK/MEKK) 
phosphorylates the serine/threonine residues on MAPK kinase (MAPKK/MEK). 
The phosphorylated MAPKK in turn activates MAPK through phosphorylation 
(58). A hallmark of MAPK is a dual-phosphorylation Thr-X-Tyr motif in the 
activation loop and both threonine and tyrosine phosphorylation are required for 
the full activity of MAPK (181). MAP kinase phosphatase (MKP) can 
dephosphorylate the threonine/tyrosine and thereby attenuate MAPK-dependent 
responses (106). 
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It has been reported that exposure to estrogens leads to rapid activation of 
the ERK 1/2 module in various cell types. In nerve cells, membrane-impermeable 
E2 rapidly induces ERK 1/2 activation, and results in c-Fos-dependent activation 
of immediate early genes (359). It has also been found that in MCF-7 breast 
cancer cells, E2 activates ERK1/2 in an ER-dependent manner (88); however, 
the upstream component involved in E2-dependent activation of this pathway is 
still unclear. Recently a study showed that in MCF-7 breast cancer cells, 
E2-induced ERK activation is mediated by a heregulin/human epidermal growth 
factor receptor-2 (ErbB2)/PKCδ/Ras pathway. In this model, HRG (Heregulin) is 
synthesized and secreted into extracellular environment upon E2 stimulation. 
HRG binds to ErbB2 resulting in activation of PKCδ, which in turn activates Ras 
and initiates downstream MAPK signaling (157). As mentioned in section 1.4.3, 
interactions between ERα, shc, and IGF-IR are also involved in E2-dependent 
activation of MAPK in MCF-7 cells. 
The p38 kinase is activated by estrogen in endothelial cells (273). In this 
cell type, E2 rapidly activates p38, leading to MAPKAP-2 kinase activation and 
phosphorylation of Hsp27. Through this pathway, E2 preserves stress fiber 
formation, and actin and membrane integrity. Moreover, E2-induced p38 
activation prevents hypoxia-induced apoptosis, and induces the migration of 
endothelial cells and the formation of primitive capillary tubes (273).  
In contrast to the other MAPK modules, E2 inhibits the JNK activity in 
breast cancer cells. In MCF-7 and ZR-75 cells, paclitaxel (taxol) or UV irradiation 
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induce apoptosis through activation of JNK. However, E2 inhibits taxol- or 
UV-stimulated JNK activity, therefore abrogating Bcl-2 and Bcl-xl phosphorylation 
and caspase activation (274). These molecular events may play a role in 
E2-dependent prevention of chemotherapy or radiation induced apoptosis in 
breast cancer cells. 
Phosphatidylinositol 3-Kinase (PI3K) 
ERα physically and functionally interacts with the regulatory subunit (p85α) 
of the lipid kinase PI3K (see section 1.4.3), and triggers activation of the catalytic 
subunit and increased intracellular production of phosphoinositides (311). PI3K 
phosphorylates the D-3 position of the phosphatidylinositol ring, catalyzing the 
synthesis of lipid mediators that act as second messengers transferring the 
signaling cascade to intracellular protein kinases. One of the principal targets of 
this cascade is the serine-threonine protein kinase Akt/protein kinase B. 
Activation of Akt mediates many of the downstream cellular effects of PI3K 
triggered by E2. For example, in vascular endothelial cells, E2 induces eNOS in 
an ERα-dependent manner via the AKT pathway (311). Activation of PI3K by 
estrogens is also important in breast cancer cells, where E2 rapidly triggers 
association of ERα with Src and p85 (50). This ternary complex probably favors 
hormone activation of Src- and PI3K-dependent pathways, which converge on 
cell cycle progression (50). There is evidence that PI3K activation by estrogen 
can also occur in the absence of ER. For example, estrogen activates PI3K in 
ER-negative MDA-MB-435 and MDA-MB-231 breast cancer cell lines and this 
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activation can be inhibited by Src kinase inhibitor PP2 but not by antiestrogen ICI 
182,780, suggesting that ER-independent pathway exists for PI3K activation 
(341). 
Other Signaling Pathways 
Protein kinase A (PKA) plays a regulatory role in mammary tumorigenesis. 
Cholera toxin (CT), a PKA activator, induces breast cancer cell growth in vitro 
and in vivo (304) and constitutive activation of PKA is associated with increased 
tamoxifen resistance in breast cancer cells (217). PKA can prevent 
ubiquitin-proteasome-dependent ERα degradation inducted by the ligand-binding 
(342). 
Estrogen rapidly induces cAMP levels and subsequently activates PKA in 
breast cancer and uterine cells through activation of adenylyl cyclase (18); 
however, the mechanism of estrogen-induced adenylate cyclase is still unknown. 
In rat pulmonary vascular smooth muscle cells, calcium removal blocked 
induction of cAMP by E2, suggesting that the intracellular calcium may have an 
important role.  
Although protein kinase C (PKC) has been identified as a target of 
nongenomic actions of E2, little is known about the mechanism (156, 330). Both 
G-protein inhibitor GDPβS and phospholipase C inhibitor U73122 block 
E2-induced PKC activity, suggesting that this process is dependent on G proteins 
as well as phospholipase C (330). Estrogen causes a rapid increase of 
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intracellular calcium levels (221), and presumably this process leads to the 
activation of calcium calmodulin-dependent kinases (CaMKs). Qin and coworkers 
reported that in MCF-7 breast cancer cells, E2 stimulates CaMKIV activity but not 
CaMKII (265), suggesting a certain specificity in E2-dependent activation of 
calcium signaling. 
1.4.5.2 ER-independent Activation of Non-genomic Pathway by Estrogens 
Several reports suggest that of E2 activation of G proteins by E2 is 
mediated directly through an orphan G protein-coupled receptor, GPR30. A 
recent report showed that E2 bound with high affinity to membranes of SKBR3 
breast cancer cells, which lack ERα and ERβ but express GPR30, and this 
resulted in activation of cAMP-dependent responses (334). Membranes from 
human embryonic kidney cells (HEK293 cells), which lack ERα, ERβ and GPR30, 
regain E2-binding activity when cells stably transfected with GPR30. GPR30 
binding is selective for E2 and the ER antagonists tamoxifen and ICI 182,780 
(105). However, it was not determined whether E2-GPR30 interactions contribute 
to the overall E2-dependent signaling or the associated downstream responses 
in breast cancer cells. 
In contrast, Revankar et al. identified GPR30 in the endoplasmic reticulum 
of COS7 monkey kidney cells expressing GPR30 linked to a fluorescent marker, 
as well as expression of endogenous GPR30 in several other cell lines (277). 
However, the process of how newly synthesized GPCRs exit the endoplasmic 
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reticulum and move to the plasma membrane was not fully characterized. GPCR 
processing in the endoplasmic reticulum is considered critical for eventual 
signaling activity and E2-initiated G protein signaling in the endoplasmic 
reticulum would be a unique mechanism to explain some of the physiological 
effects associated with E2 (199).  
 
1.5 Research Objectives 
1.5.1 Objective 1 
Treatment of mammalian cells with mitogens, cytokines and differentiation 
inducing agents is accompanied by alterations in expression of multiple genes 
that play integral roles in mediating cell-specific responses (325, 326). For 
example, immediate-early genes such as c-fos are rapidly induced (0.3 - 2 hr) in 
several mammalian cell lines after treatment with mitogens. c-fos protein is a 
nuclear transcription factor that forms part of the activating protein-1 (AP-1)
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complex and regulates AP-1-dependent gene expression. The early growth 
response-1 (Egr-1) gene is also a member of the immediate-early gene group of 
transcription factors and at least 4 Egr genes have been identified. Egr-1 protein 
contains a highly conserved DNA-binding domain composed of three zinc fingers, 
and binds GC-rich promoter DNA sequences (66, 355). Egr-1 modulates 
transcription of multiple genes and the overall genomic and cellular responses to 
Egr-1 are complex and dependent on both promoter- and cell-context. 
In prostate cancer, Egr-1 plays a role in cancer progression. Expression 
levels of Egr-1 mRNA and protein are much higher in prostate adenocarcinoma 
compared to levels in normal prostate tissue (332). Moreover, levels of Egr-1 
protein expression correlate with Gleason scores and inversely correlate with the 
degree of differentiation of carcinoma cells (95, 332). Abdulkadir and co-workers 
used the transgenic mouse model to study the function of Egr-1 over-expression 
in prostate tumors in vivo. Their data showed that tumor formation was 
significantly delayed in Egr-1 deficient mice, but tumor initiation and tumor growth 
rates were not affected by loss of Egr-1(5). Baron and co-workers using Egr-1 
antisense oligonucleotides and successfully inhibited transformation of prostate 
cancer cells (26). These results indicated a unique role for Egr-1 in regulating the 
transition from localized carcinoma in situ to invasive carcinoma. Egr-1 is induced 
in some but not all cancer cell lines after treatment with serum, ultraviolet light or 
phorbol esters, and there were differences in Egr-1 inducibility even among 
ER-positive MCF-7 (inducible), ZR-75 and T47D breast cancer cell lines (137). 
     
 84
Egr-1, like several other immediate-early genes is induced by E2 in the rodent 
uterus and in MCF-7 breast cancer cells (67, 329). Pratt and coworkers reported 
that E2 activates Egr-1 expression in MCF-7 cells (263), and this is accompanied 
by rapid autophosphorylation of raf-1 suggesting that hormonal regulation of 
Egr-1 may involve rapid non-genomic pathways of estrogen action which have 
been extensively described in multiple cell types (189, 358). The -600 to +12 
region of the Egr-1 promoter contains several potential E2-responsive motifs 
including a distal GC-rich motif that could be activated by nuclear ERα/Sp1, and 
multiple SREs (SRE1-4) and cAMP response element (CRE) that can be 
hormonally activated through non-genomic pathways. The first objective of this 
study was to investigate the molecular mechanism of E2-dependent activation of 
Egr-1 in MCF-7 breast cancer cells and identify which cis-response elements and 
trans-acting factors in the Egr-1 promoter are required for E2 induced 
transactivation.   
1.5.2 Objective 2 
Chicken ovalbumin upstream promoter transcription factors (COUP-TFs) 
are orphan receptors and members of the nuclear receptor superfamily. Two 
genes called COUP-TFI (also termed EAR3) and COUP-TFII (also termed ARP-1) 
have been identified in mammals. These receptors are closely related 
transcription factors that are widely expressed and are involved in the regulation 
of several important biological processes, such as neurogenesis, organogenesis, 
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cell fate determination, and metabolic homeostasis (242). Both genes show an 
exceptional homology and overlapping expression patterns, suggesting that they 
may serve redundant functions. However, each factor possesses its own distinct 
expression profile during development (197). A null mutation of COUP-TFI 
resulted in defects in neurogenesis, axon guidance, and arborization (267), 
whereas deletion of COUP-TFII resulted in striking defects in angiogenesis, 
vascular remodeling, and fetal heart development (248). 
Like most nuclear receptors, as transcription factors, COUP-TFI regulates 
transcription by binding to a variety of response elements, such as DR1, DR3, 
DR4 DR5 and DR7 containing the AGGTCA motif in target gene promoters. 
COUP-TFI was originally identified as an activator of the chicken ovalbumin gene. 
In the arrestin gene promoter, a DR-7 element mediated the positive 
transcriptional effect of COUP-TF (200) and recently COUP-TFI was shown to 
activate aldosterone synthase (CYP11B2) expression by binding to the -129/-124 
element of human CYP11B2 promoter (306). However, in the other genes 
COUP-TFI activated transcription through protein-protein interactions with other 
transcription factors. For example in the HNF-1α gene COUP-TFI interacted with 
HNF-4 in the promoter (213) and in the Egr-1 gene COUP-TF enhances 
transcription by recruiting coactivator SRC-1 through its interaction with Sp-1 
(260). It has also been reported that COUP-TFI can function as a transcriptional 
repressor of many target genes and several mechanisms have been proposed to 
explain the COUP-TF-mediated repression. COUP-TFs inhibit the transcription of 
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other nuclear receptor such as retinoic acid receptor and thyroid hormone 
receptor by competing for binding to the response elements of these receptors, 
thus acting as passive repressors of their transcriptional activation (343). Another 
mechanism of passive repression by COUP-TFs involves their ability to 
heterodimerize with the 9-cis retinoic acid receptor, reducing its availability for 
other nuclear receptors that use it as a partner (384). Furthermore, COUP-TFI 
represses basal transcriptional activity by interacting with transcriptional 
corepressors, such as N-CoR and SMRT (308).  
It has also been reported that COUP-TFI enhanced human ER activity as 
a transcription coactivator. The formation of a tight ERα-COUP-TFI intermediate 
complex resulted in an increased recruitment of ERK2/p42 MAPK, 
phosphorylation of ERα on Ser 118 and enhanced transcriptional activity (215). 
However, the functional domains of COUP-TFI required for enhancement of ERα 
activity, and interactions with ERα have not been determined. The second 
objective of this study was to investigate COUP-TFI coactivation activity on ER 
and ER/Sp1 genomic transactivation pathway and also identify the functional 
domains of COUP-TFI required for this enhanced activity, and for interactions 
with ERα and Sp1. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1 Chemicals, Cells, and Antibodies   
MCF-7, ZR-75, and MDA-MB-231 breast cancer cells, HeLa, and COS-7 
cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). MCF-7 and MDA-MB-231 cells were routinely maintained in 
DME/F12 medium with phenol red and supplemented with 5% fetal bovine serum 
(FBS) plus antibiotic antimycotic solution (Sigma, St. Louis, MO). COS-7 and 
HeLa cells were maintained in Dulbecco’s Modified Eagle Media (DMEM) (Gibco 
Invitrogen Corporation, Carlsbad, CA) medium with phenol red and 
supplemented with 5% FBS plus antibiotic antimycotic solution. ZR-75 cells were 
maintained in RPMI 1640 media (Sigma) supplemented with 2.2 g/L sodium 
bicarbonate, 2.38 g/L HEPES, 0.11 g/L sodium pyruvate, 4.5 g/L glucose, and 
7.5 % FBS plus antibiotic antimycotic solution. Cells were cultured and grown in 
an air-carbon dioxide (95:5) atmosphere at 37°C. For transient transfection 
studies, cells were grown for 1 day in DME/F12 medium without phenol red and 
2.5% FBS stripped with dextran-coated charcoal. ICI 182780 was kindly provided 
by Dr. Alan Wakeling (AstraZenaca Pharmaceuticals, Macclesfield, UK). The 
kinase inhibitors PD98059, LY294002, SB202190 and SP600125 were 
purchased from Cal-Biochem (La Jolla, CA). ERα, Sp1, Elk-1, actin, 
phospho-Elk-1, and SRF antibodies were obtained from Santa Cruz 
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Biotechnology, Inc. (Santa Cruz, CA). Myc-tag and Egr-1 antibodies were 
obtained from Cell Signaling Technology (Beverly, MA). His-tag antibody was 
obtained from Invitrogen (Carlsbad, CA). All other chemicals and biochemicals 
were the highest quality available from commercial sources. 
 
2.2 Cloning and Plasmids  
2.2.1 Egr-1 Experiment 
Wild-type human ERα (ERα) expression plasmid was provided by Dr. 
Ming-Jer Tsai (Baylor College of Medicine, Houston, TX). The SRF-luc construct 
contains five tandems SRF elements linked to bacterial luciferase and was 
purchased from Stratagene (La Jolla, CA). Dominant negative (dn) Elk-1 was 
provided by Dr. Roger Davis (University of Massachusetts, Worcester, MA). This 
construct encodes amino acid residues 1 - 168 of Elk-1 and lacks the activation 
domain. The plasmid Gal-Elk-1C was obtained from Dr. Roger Treisman 
(Imperial Cancer Research Center, London, UK). pEgr1-CAT plasmid, which 
contains the -600 to +12 5’ flanking sequence from the human Egr-1 gene was 
kindly provided by Dr. Kathy Sakamoto (UCLA School of Medicine, Los Angeles, 
CA). pEgr-1A (-600/+12), pEgr-1B (-460/+12), pEgr-1C (-164/+12), pEgr-1D 
(-480/-285), pEgr-1E (-480/-324), and pEgr-1F (-480/-348) were made by PCR 
amplification using pEgr1-CAT as template. The PCR products were purified and 
ligated into pGL2 basic vector (Promega Corp., Madison, WI). Site-directed 
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mutagenesis was performed using the two-step overlap extension PCR method. 
Oligonucleotides used for site-directed mutagenesis in this study are listed as 
Table 2-1.  
 
 
 
Table 2-1 Oligonucleotides used for site-directed mutagenesis. 
pEgr-1Em1  5’ GCA GCA CCT TCC TTG GAG TGG C 3’ 
pEgr-1Em2  5’ GAA CAA CCC TTG CTT GGG CAG CAC 3’ 
pEgr-1Em3  5’ GAT CCC CCG CCT AGC TAA CCC TTA TTT GG 3’ 
Elk-1c (S383A)  5’ GAG CAC CCT GGC TCC CAAT TGC GC 3’ 
5’ TGC GCC CCG TGC CCC GGC CAA GC 3’ Elk-1C (S389A) 
Note. Mutations are underlined and substituted bases are indicated in bold. 
2.2.2 COUP-TFI Experiment 
Taf1-ERα and Null-ERα expression plasmids were provided by Dr. D. 
McDonnell (Duke University, Durham, NC). The human ER deletion construct 
19c-ERα was provided by Dr. Pierre Chambon (Institut de Genetique et de 
Biologie Moleculaire et Cellulaire, Illkirch, France). The SRC-1 expression 
plasmid was graciously provided by Dr. B. O'Malley (Baylor College of Medicine, 
Houston, TX). The pERE3 reporter containing three consensus ERE sites linked 
to a luciferase gene was created by cloning an oligonucleotide with three ERE 
elements into
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BamHI-HindIII cut pXP-2 plasmid (298). The wild-type mouse COUP-TFI 
expression vector (pCR3.1-COUP-TFI) was originally provided by Dr. Ming-Jer 
Tsai (Baylor College of Medicine) and used as the PCR template for further 
cloning. The COUP-TFI expression plasmids used in the transfection assay 
including WT, N-terminal deletion mutants (dN1, and dN2), and C-terminal 
deletion mutants (dC1 and dC2) were generated by PCR amplification and 
ligated into pCDNA3.1/His or pCDNA3.1/HIS/-Myc vectors (Invitrogen). The 
COUP-TFI dN3 mutant were generated by PCR amplification and cloned into pM 
vector (BD Biosciences Clontech, Palo Alto, CA). For mammalian two-hybrid 
assay, the expression plasmids of GAL4-DBD-ERα chimeras including pM-ER, 
pM-ER (A/B) and pM-ER (C/F) were made by Dr. B. Saville in this lab as 
previously described (298). The VP-16-COUP-TFI chimera expression plasmid 
was generated by PCR amplification and ligted into pACT vector (Promega). The 
expression plasmids of point mutation of COUP-TFI (m83, m103 and m138) were 
generated by site-directed mutagenesis using the two-step overlap extension 
PCR method and ligated into pCDNA3.1/His vector. Oligonucleotide primers 
used for cloning or site-directed mutagenesis in this study are listed in Table 2-2.  
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Table 2-2 Summary of primers used for cloning the COUP-TFI constructs. 
Clones Primers 
F, 5’ GCGGCCGCATGGCAATGGTAGTTAG 3’ 
R, 5' GCTGCTCGAGGGAACACTGGATGGACATGT 3' 
WT 
F, 5' TATAGGTACCTGGTTCAGGCCAGAGCCAGCAGCA 3'
R, 5' GCTGCTCGAGGGAACACTGGATGGACATGT 3' 
dN1 
F, 5' TAGCGGTACCTAGGAGCGTCCGCAGGAACTTAAC 3'
R, 5' GCTGCTCGAGGGAACACTGGATGGACATGT 3' 
dN2 
F, 5’ TCTAGAATGGAAGCGGTTCAGCGAGGAA 3’ 
R, 5’ GCGGCCGCCTAGGAACACTGGATGG 3’ 
dN3 
F, 5’ AGCTAAGCTTATGGCAATGGTAGTTAGCAG 3’ 
R, 5’ AGCTCTCGAGCAGCAGTTTGCCAAAGCGGC 3’ 
dC1 
F’ 5’ AGCTAAGCTTATGGCAATGGTAGTTAGCAG 3’ 
R’ 5’ AGCTCTCGAGCAGCGGCATGGAGCAC 3’ 
dC2 
F, 5’ ACGCGTCAATGGCAATGGTAGTTAG 
R, 5’ TCTAGACTAGGAACACTGGATGG 
VP16-COUP 
F, 5’ GCACATCGAGGCCGTGGTGTGCG 3’ 
R, 5' CGCACACCACGGCCTCGATGTGC 3' 
m83 COUP-TFI 
F, 5’ CTGCGAGGGCGCCAAAAGTTTCT 3’ 
R, 5' AGAAACTTTTGGCGCCCTCGCAG 3' 
m103 COUP-TFI 
F, 5’ GTGCCAATACGCCCGCCTCAAGAAG 3’ 
m138 COUP-TFI 
R, 5' CTTCTTGAGGCGGGCGTATTGGCAC 3' 
Mutations are underlined and substituted bases are indicated in bold.
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2.3 Transient Transfection and Luciferase Assay  
2.3.1 Egr-1 Experiment 
For transfection experiments, 175,000 MCF-7 cells were initially seeded in 
12-well plates. Twenty-four h after seeding, MCF-7 cells were transfected by the 
calcium phosphate method with Egr-1 promoter-luciferase reporter constructs, 
ERα expression vector and pCDNA3/His/lacZ (Invitrogen) that was used as a 
standard reference control plasmid for determining transfection efficiencies. After 
5 h, cells were shocked with 25% glycerol and washed with PBS. Fresh 
DME/F12 without phenol red and charcoal-stripped FBS containing DMSO or 1 
nM E2 in DMSO were added to the cells and incubated for 24 h.  
2.3.2 COUP-TFI Experiment 
MCF-7, MDA-MB231, HeLa, COS-7 and ZR-75 cells were seeded in 
DME/F-12 medium without phenol red containing 2.5 % 
dextran/charcoal-stripped FBS. After 24 h cells were transfected with GeneJuice 
transfection reagent (Novagen, Madison, WI) according to manufacture's 
recommendation. Five hours after transfection, cells were replaced with fresh 
DME/F12 without phenol red and treated with DMSO or 10 nM E2 for 36 h. 
Cells from each experiment were then harvested in 100 μl of 1X Reporter 
lysis buffer (Promega). Luciferase assays were performed on 30 μl of the cell 
extract using the Luciferase assay system (Promega). Light emission was 
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detected on a Lumicount luminometer (Packard, Meriden, CT). β-Galactosidase 
assays were performed on 20 μl of cell extract using the luminescent 
Galacton-Plus assay kit (Tropix, Bedford, MA). The luciferase activity observed in 
each treatment group was normalized to β-gal activity obtained from the same 
sample to correct for transfection efficiencies. Data are expressed as fold 
induction (by E2 or other chemicals) compared to the solvent (DMSO) control.  
 
2.4 Western Blot Assay   
Cells were seeded into 60 mm tissue culture plates in DME/F-12 medium 
without phenol red containing 2.5% charcoal-stripped FBS. After 24 h, cells were 
treated with 10 nM E2 and harvested at designated time points and lysed in 
ice-cold lysis buffer (50 mM HEPES [pH 7.5], 500 mM NaCl, 10% [vol/vol] 
glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA) supplemented with 
protease inhibitor cocktail (Sigma). Equal amounts of protein from each treatment 
group were boiled in 1x Laemmli buffer (50 mM Tris-HCl, 2% sodium dodecyl 
sulfate [SDS], 0.1% bromphenol blue, 175 mM β-mercaptoethenol), separated by 
SDS-10% polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to 
polyvinylidene difluoride (PVDF) membrane. Membranes were blocked with 
Blotto (5% milk, Tris-buffered saline [10 mM Tris-HCl, pH 8.0, 150 mM NaCl], and 
0.05% Tween 20) and probed with primary antibodies. Following incubation with 
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peroxidase-conjugated secondary antibody, immunoglobulins were visualized 
using the ECL detection system (Perkin Elmer Foster City, CA). 
 
2.5 Nuclear Extract Preparation and EMSA 
Cells were seeded in 100 mm tissue culture plates using DME/F12 without 
phenol red, supplemented with 2.5% charcoal-stripped FBS. After 24 h, cells 
were treated for 1 h with DMSO or 10 nM E2. Nuclear extracts were obtained 
using the NE-PER nuclear and cytoplasmic extraction kit (Pierce) according to 
the manufacturer's instructions. Nuclear extracts obtained from different 
treatment groups were incubated for 20 min in HEGD buffer with poly-(dI-dC), 
unlabeled oligonucleotides or antibodies for supershift assays. The mixture was 
then incubated for additional 20 min after addition of 32P-labeled oligonucleotide. 
Reaction mixtures were separated on 5% polyacrylamide gels 
(acrylamide:bis-acrylamide 30:0.8) at 140 V in 1X TBE (0.09 M Tris-HCl, 0.09 M 
boric acid and 2 mM EDTA, pH 8.3). Gels were dried and protein-DNA complexes 
were visualized using a Storm 860 instrument (Amersham Biosciences, 
Piscataway, NJ). Oligonucleotides used for EMSA in this study are summarized 
as follows (mutations are underlined and substituted bases are indicated in bold). 
SRE3  5’ AGG ATC CCC CGC CGG AAC AAC CCT TAT TTG GGC AG 3’
mTCF 5’ AGG ATC CCC CGC CTA GCT AAC CCT TAT TTG GGC AG 3’ 
5’ AGG ATC CCC CGC CGG AAC AAC CCT TGC TTG GGC AG 3’mSRF 
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2.6 RT-PCR Assay  
Total RNA was extracted using Nucleospin RNA purification kit (BD 
Biosciences Clontech), following the manufacturer’s instructions. An aliquot of 
750 ng RNA was used as the template for cDNA synthesis by incubating with 
oligo-d(T) primer and multiscribe reverse transcriptase (Perkin Elmer) at 48°C for 
40 min. PCR amplification was performed with Taq PCR Master Mix (Promega, 
Madison, WI). The following conditions were used for the PCR assays: one cycle 
of 2 min at 95°C; 34 cycles of 30 sec at 95°C; 30 sec at 57.5°C; 1 min at 72°C; 
one cycle of 5 min at 72°C. PCR products were analyzed by electrophoresis on 
1.5% agarose gels containing ethidium bromide. Oligonucleotide primers used 
for PCR in this study include the following 
F’ 5’ GAG CCG AGC GAA CAA CCC TAC GAG CAC CTG 
R’ 5’ GCG CTG AGG ATG AAG AGG TTG GAG GGT TGG 
Egr-1 
F’ 5’ TGT GTC CGT CGT GGA TCT GA 
R’ 5’ CCT GCT TCA CCA CCT TCT TGA 
GADPH 
F, 5’ GCT TCA ACG CAG ACT ACG AG 
c-fos 
R, 5’ TAG AAG GAC CCA GAT AGG TC 
 
2.7 Coimmunoprecipitation Assay 
COS-7 cells were seeded into 60 mm tissue culture plates in phenol 
red-free DME/F-12 medium containing 2.5% charcoal-stripped FBS. After 24 h., 
transient transfections were performed by using GeneJuice transfection reagent 
(Novagen) according to the manufacturer's protocol. After 4-6 h., transfected cells 
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were treated with 10 nM E2 for 24h. Cells were harvested and lysed by using 1 
ml of RIPA buffer (1x PBS, 1% Nonidet P-40 or Igepal CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 10 mg/ml PMSF in isopropanol, aprotinin, 100 mM 
sodium orthovanadate), and cellular debris was removed by centrifugation at 
10,000xg for 10 min at 4ºC. The supernatant was transferred to a fresh 
microcentrifuge tube and precleared by adding 20 µl of protein A-agarose 
conjugate slurry (Sigma) and incubated at 4ºC for 1h. After centrifugation for 1 
min, the supernatant was transferred to another new microcentrifuge tube, and 
2.5 µg of rabbit polyclonal anti-ERα antibody (Santa Cruz) was added and 
incubated at 4 ºC for 1 hr. After incubation, 20 µl of protein A-agarose conjugate 
slurry (Sigma) was added and incubated at 4ºC for another 1 h. The 
immunoprecipitate was collected by centrifugation, gently washed with 500 µl 
RIPA buffer (3X), and resuspended and denatured in 50 µl of 2x Laemmli buffer. 
The immunoprecipitated sample was analyzed in a western blot assay.  
 
2.8 Statistical Analysis  
Statistical significance was determined by ANOVA and Student's t-test, 
and the levels of probability are noted. The results are expressed as means ± SD 
for at least three separate (replicate) experiments for each treatment.
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CHAPTER III 
RESULTS 
3.1 Egr-1 Is Activated by E2 in MCF-7 Cells 
3.1.1 Deletion and Mutational Analysis of the Egr-1 Gene Promoter 
The results in Figure 3-1 A show that E2 induced Egr-1 protein levels by 
approximately 8.2-fold, and this complements results of previous studies in 
MCF-7 cells which show that E2 induces Egr-1 mRNA levels (263). E2 did not 
induce luciferase activity in MCF-7 cells transfected with pEgr-1A alone; however, 
in cells cotransfected with ERα expression plasmid (500 ng), E2 induced 
luciferase activity (> 7-fold), and this response was inhibited by the antiestrogen 
ICI 182780 (Fig. 3-1 B). Thus, hormone-responsiveness in MCF-7 cells was 
observed only after cotransfection with ERα. Similar results have previously been 
reported for multiple E2-responsive plasmids activated through nuclear or 
extranuclear pathways of estrogen action, and this is related to limiting levels of 
ERα in transfected cells that overexpress the plasmids (88-90, 297, 331). 
However, it was also observed that higher concentrations of E2 also significantly 
induced luciferase activity in MCF-7 cells transfected only with pEgr-1A (no hERα 
cotransfection) (Fig. 3-1 C). This has also been reported for hormone-dependent 
activation of constructs containing c-fos promoter inserts which are activated 
through kinase-dependent pathways in MCF-7 cells (88, 89). 
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The -600 to +12 region of the Egr-1 promoter contains several potential 
E2-responsive motifs including a distal GC-rich motif that could be activated by 
ERα/Sp1 (nuclear), multiple SREs (SRE1-4), and cAMP response element (CRE) 
that can be hormonally activated through non-genomic (extranuclear) pathways 
(51, 85, 88, 189, 294). Transfection studies in MCF-7 cells with pEgr-1A (-600 to 
+12), pEgr-1B (-460 to +12), and pEgr-1C (-164 to +12) (Fig. 3-2 A) show that the 
upstream GC-rich and downstream CRE and SRE1 motifs are not necessary for 
hormone-inducibility suggesting the SREs 2 – 4 are necessary for this response. 
The E2-responsiveness of several 3'-deletion constructs containing SREs 2 – 4 
(pEgr-1D, -480 to -285), SRE4 and 3 (pEgr-1E, -480 to -324), and SRE4 
(pEgr-1F, -480 to -376) were also investigated in MCF-7 cells (Fig. 3-2 B) and 
induction by E2 was observed only for the former two constructs. These results 
suggest that SRE3 was required for E2-induced transactivation. Mutation 
analysis of SRE3 was determined using constructs containing selective 
mutations in the SRF (SRE2 and SRE3) and TCF (SRE3) motifs. E2-induced 
transactivation was observed in cells transfected with pEgr-1Em1 which 
contained a mutation in an adjacent SRF binding site. However, induction was 
not observed in cells transfected with constructs containing SRE3 mutations in 
the SRF or TCF sites (pEgr-1Em2 and pEgr-1Em3) (Fig. 3-2 C). These results 
indicate that SRE3 is the major E2-responsive motif in the Egr-1 gene promoter 
and that TCF and SRF motifs are required. 
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A. 
Time (h) 0 2 4 246 48
Egr-1
Actin
 
 
 
Fig. 3-1. Hormone-responsiveness of Egr-1 in MCF-7 cells.  (A) Induction of 
Egr-1 protein by E2. MCF-7 cells were treated with 10 nM E2 for different times 
and levels of Egr-1 protein were determined by Western blot analysis as 
described in the Materials and Methods. Actin protein was used as a loading 
control, and these cells were not cotransfected with ERα. (B) Hormone activation 
of pEgr-1A. MCF-7 cells were transfected with pEgr-1A with or without ERα 
expression plasmid, treated with DMSO, E2, ICI 182780, or their combination, 
and luciferase activity was determined as described in the Materials and Methods. 
Results are expressed as means ± SD for three replicate determinations for each 
treatment group, and significant (p < 0.05) induction by E2 (*) or inhibition by ICI 
182780 (**) is indicated. (C) Activation of pEgr-1A in the absence of 
cotransfected ERα. Cells were transfected with pEgr-1A, treated with 1 – 1000 
nM E2, and luciferase activity was determined as described in the Materials and 
Methods. Results are expressed as means ± SD for three replicate 
determinations for each treatment group, and significant (p < 0.05) induction by 
E2 (*) is indicated.. 
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Fig. 3-1. continued. 
     
 101
 
A. 
SRECRESp1 TATASRE SRE
SRECRE TATASRE
SRECRE TATA
SRE
-600
-460
-164
*
*
pEgr-1A
pEgr-1B
pEgr-1C
DMSO
1 nM E2
0 1 2 3 4 5
Fold Induction
6
+12
+12
+12
 
 
Fig. 3-2. Deletion and mutation analysis of the Egr-1 gene promoter.  Deletion (A, 
B) and mutation (C) analysis of pEgr-1A. MCF-7 cells were transfected with 
pEgr-1 constructs and ERα expression plasmid, treated with DMSO or 1 nM E2, 
and luciferase activity was determined as described in the Materials and Methods. 
Results are expressed as means ± SD for three replicate determinations for each 
treatment group, and significant (p < 0.05) induction by E2 is indicated by an 
asterisk.
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Fig. 3-2. continued. 
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3.1.2 Protein Interactions with SRE3 
Nuclear extracts from DMSO and E2-treated MCF-7 cells were incubated 
with [32P]SRE3 and analyzed in a gel mobility shift assay (Fig. 3-3). In this gel, 
two major specifically-bound retarded bands were formed (see arrow) using 
DMSO and E2-treated extracts (lanes 2 and 6). Coincubation of both extracts 
with [32P]SRE3 and Elk-1 (lanes 3 and 7) or phospho-Elk-1 (lanes 4 and 8) 
antibodies gave supershifted bands (SS →) indicating that both forms of Elk-1 
were associated with the SRE oligonucleotide. Although the overall intensities of 
the retarded bands were comparable using both E2- and solvent (DMSO)-treated 
nuclear extracts, the supershifted phospho-Elk-1 complex was more intense 
using the hormone-treated extracts (lane 4 vs. lane 8). In competition 
experiments with unlabeled oligonucleotides (lanes 9 - 11), mutant 
oligonucleotides in the TCF (m1-SRE3) and SRF (m2-SRE3) sites only slightly 
decreased the more and less mobile retarded bands, respectively. In contrast, 
competition with the wild-type SRE3 oligonucleotide resulted in complete loss of 
both retarded bands. Antibody supershift experiments were also carried out using 
[32P]SRE3 and nuclear extracts from DMSO- and E2-treated cells with SRF 
antibody. SRF antibody can also induce formation of a supershifted complex in 
both treatment groups (data not shown). These data are consistent with 
E2-induced phosphorylation of Elk-1 and interaction of SRF and phospho-Elk1 
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Fig. 3-3. Gel mobility shift assay of SRE3-protein interactions.             
Interactions of nuclear extracts with [32P]SRE3. [32P]SRE3 was incubated with 
nuclear extracts from MCF-7 cells treated with DMSO or E2 and coincubated with 
Elk-1, phospho-Elk-I antibodies, or non-specific IgG or unlabeled 
oligonucleotides (100-fold excess), and analyzed by gel mobility shift assay as 
described in the Materials and Methods. Retarded and supershifted bands are 
indicated with arrows.   
     
 105
on SRE3 in the Egr-1 gene promoter, and this was comparable with SRF/Elk-1 
interactions with the SRE in the c-fos gene promoter (88). 
3.1.3 Role of Elk-1 in Activation of Egr-1 Gene Expression 
The role of Elk-1 in activation of Egr-1 was further investigated in the 
MCF-7 cells transfected with pEfg-1D and increasing amounts of dominant 
negative (dn) expression plasmid for Elk-1 (50 - 500 ng) (Fig. 3-4 A). dn-Elk-1 
inhibits E2-induced activation of pEgr-1D and confirms the role of Elk-1 in 
activation of SRE3. GAL4-Elk-C contains the C-terminal region of Elk-1 (amino 
acids 307 - 428) fused to the DNA binding domain of the yeast GAL4 proteins. 
The Elk-C region can serve as a transactivation domain (206, 338), and in the 
presence of cotransfected ERα, E2 induces reporter gene activity in MCF-7 cells 
transfected with GAL4-Elk-C and a construct containing 5 copies of the GAL4 
response element linked to a bacterial luciferase reporter gene (pGAL45) (Fig. 
3-4 B). This construct is also induced by E2 alone (ca. 2-fold), but is enhanced by 
cotransfection with ERα due to overexpression of the reporter construct and 
limiting levels of endogenous ERα (88). This hormone-induced response was 
inhibited by the MAPK kinase inhibitor PD98059 but not by 20 μM SB202190 or 
25 μM SP600125 which inhibit p38 and jun N-terminal kinase, respectively. 
These results are consistent with hormonal activation of the ras-MAPK pathway 
in breast cancer cells (219, 220). The results illustrated in Figure 3-4 C compared 
the differences in hormone-induced activation of wild-type Elk-C and constructs 
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containing S383A and S389A mutations. E2 activates wild-type GAL4-ElkC and 
partially activates the S389A mutant but not the S383A mutant, and this pattern 
of activation was similar to that observed for serum activation of Elk-1 in NIH 3T3 
cells (206). The results in Figure 3-4 D demonstrate that E2 induces 
phosphorylation of Elk-1, and this is inhibited by PD98059 but not SB02190, 
confirming the role of MAPK in this response. 
However, previous studies indicate that the SRE in the c-fos gene 
promoter is also activated through phosphatidylinositol-3-kinase (PI3-K) which is 
upregulated by E2 in MCF-7 cells (88). Results in Figure 3-5 A show that the 
MAPK inhibitor PD98059 inhibits E2-induced transactivation in MCF-7 cells 
transfected with pEgr-1E, whereas this response is not blocked by LY294002, an 
inhibitor or PI3-K. As a positive control, LY294002 but not PD98059 inhibited 
E2-dependent activation of a construct containing 5 SRF elements (SRF-luc) in 
MCF-7 cells (Fig. 3-5 B) as previously reported (89). Induction of Egr-1 mRNA 
levels by E2 (Fig. 3-5 C) were also inhibited by PD98059 and not LY294002 
confirming that hormonal activation of Egr-1 is dependent on ERα and 
kinase-dependent activation of MAPK. In contrast, hormone-dependent 
activation of c-fos is due to activation of both MAPK and PI3-K pathways (88, 89), 
and inhibitors of these pathways decrease induction of c-fos mRNA in MCF-7 
cells (Fig. 3-5 C). 
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Fig. 3-4. Role of Elk-1 phosphorylation in activation of Egr-1.  (A) Effects of 
dnElk-1. MCF-7 cells were transfected with pEgr-1D, treated with DMSO or 1 nM 
E2, cotransfected with different amounts of dnElk-1 expression plasmid, and 
luciferase activity was determined as described in the Materials and Methods. 
Significant (p < 0.05) inhibition of E2-induced luciferase activity by dnElk-1 is 
indicated by an asterisk. (B) Hormone activation of GAL4-Elk-1C/pGAL45. MCF-7 
cells were transfected with GAL4-Elk-1C/pGAL45, ERα expression plasmid, 
DMSO, 10 nM E2 and kinase inhibitors (50 μM PD98059, 20 μM SB202190, and 
25 μM SP600125), and luciferase activities were determined as described in the 
Materials and Methods. Significant (p < 0.05) inhibition of E2-induced activity is 
indicated (**). (C) Activation of GAL4-Elk-1C. MCF-7 cells were transfected with 
pGAL45, wild-type and mutant GAL4-Elk-1C, (±) ERα expression plasmid, 
treated with DMSO or 10 nM E2, and luciferase activity was determined as 
described in the Materials and Methods. Significant (p < 0.05) induction by E2 is 
indicated by an asterisk. (D) Phosphorylation of Elk-1. MCF-7 cells were treated 
with DMSO, 10 nM E2 alone, or in combination with 50 μM PD98059 or 20 μM 
SB202190, and whole cell lysates were examined by Western blot analysis for 
Elk-1 and phospho-Elk-1 proteins. Similar results were observed in duplicate 
experiments. Results in (A), (B) and (C) are means ± SD for three replicate 
experiments for each treatment group.
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Fig. 3-4. continued. 
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Fig. 3-5. Effects of PD98059 and LY294002 on hormone-induced activation of 
Egr-1 and comparative SRE sequences.  (A) Activation of pEgr-1E. MCF-7 cells 
were transfected with pEgr-1E, treated with DMSO, 10 nM E2 alone or in 
combination with 25 μM PD98059 or 50 μM LY294002, and luciferase activity 
was determined as described in the Materials and Methods. Results are means ± 
SD for three replicate experiments for each treatment group, and significant (p < 
0.05) inhibition in cotreatment groups is indicated (*). (B) Induction of SRF-luc by 
E2. MCF-7 cells were transfected with SRF-luc, treated with E2, DMSO or kinase 
inhibitor as indicated in Fig. 3-5 A (above), and luciferase activity determined as 
described in the Materials and Methods. Results are means ± SD for three 
replicate determinations for each treatment group, and significant (p < 0.05) 
induction (*) or inhibition (**) is indicated. (C) Induction of pEgr-1 and c-fos mRNA. 
MCF-7 cells were treated with DMSO, 10 nM E2 alone or in combination with 25 - 
50 μM PD98059 or 25 - 50 μM LY294002, and induction responses were 
determined by RT-PCR as described in the Materials and Methods. Similar 
results were observed in duplicate experiments.   
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Fig. 3-5. continued. 
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3.2 COUP-TFI Coactivates ERα-Mediated Transactivation 
3.2.1 Coactivation of ERα by COUP-TFI 
Coactivation of ERα-dependent transactivation by COUP-TFI was initially 
examined in ERα-positive MCF-7 breast cancer cells. MCF-7 cells were 
transfected with pERE3, which contains three tandem EREs in a minimal 
TATA-luciferase construct, and ERα expression plasmid. The transfected pERE3 
construct is overexpressed in the transfected cells and minimal E2-inducibility is 
observed in MCF-7 cells in the absence of co-transfected ERα. This system is 
ideal for investigating coactivation of ERα and determining domains of ERα and 
coactivators required for E2-dependent transactivation in a breast cancer cell 
context. The results in Figures 3-6 A show that E2 causes a 1.6-fold increase in 
reporter gene activity in MCF-7 cells transfected with 2.5 ng ERα expression 
plasmid, and cotransfection with 50, 100 and 200 ng COUP-TFI expression 
plasmid resulted in a 7.9-, 5.5- and 9-fold enhancement of E2-induced luciferase 
activity. COUP-TFI alone also increased basal activity and this modified the 
overall enhanced activity by COUP-TFI. To determine the cell specificity of 
coactivation by COUP-TFI, we also tested ERα-negative breast (MDA-MB 231) 
and non-breast cancer (COS-7 and HeLa) cells. In MDA-MB 231, COS-7 and 
HeLa cells, E2-induced luciferase activity was observed only after cells 
transfected with ERα, and COUP-TFI expression significantly enhanced 
E2-dependent activity up to 30.7-,10.3- and 3.7-fold respectively (Figs. 3-6 B, C  
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Fig. 3-6 Coactivation of ERα by COUP-TFI. (A) MCF-7, (B) MDA-MB-231, (C) 
COS-7 and (D) HeLa cells were transfected with pERE3, ERα, β-galactosidase 
and increasing amounts of pCDNA3-COUP-TFI (0, 50, 100 and 200 ng) 
expression plasmid. After transfection, cells were treated with DMSO or 10 nM 
E2 for 36 h., and luciferase activity normalized to β-galacosidase activity was 
determined as described in the Materials and Methods and presented as relative 
luciferase units (RLU). Significant (p<0.05) induction by E2 (*) or coactivation of 
E2-induced activity by COUP-TFI (**) is indicated. 
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Fig. 3-6. continued. 
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and D). These results show that COUP-TFI significantly coactivated 
ERα-mediated transactivation in ERα-positive and negative breast cancer cells 
and in ERα-negative COS-7 and HeLa cells and suggest that this coactivation 
response is primarily due to COUP-TFI and commonly expressed cofactors.  
3.2.2 Coactivation of Variant ERα by COUP-TFI 
ERα contains two major activation domains and we therefore investigated 
the coactivation activity of COUP-TFI with three ERα variants as shown in Figure 
3-7 A. The Taf1-ERα contains three mutations in helix 12 (D538N, E542Q, and 
D545N) that block AF2-dependent interaction with coactivators and inactivates 
AF-2-dependent transcriptional activation. The 19c-ERα is an A/B domain 
deletion mutant which lacks AF1. The Null-ERα which contains mutations on AF2 
and deletion of AF1 has the minimal hormone response (74). 
When COS-7 cells transfected with pERE3 and COUP-TFI plasmid alone, 
COUP-TFI did not affect basal luciferase activity after treatment with E2 (Fig. 3-7 
B), suggesting that enhancement of E2-induced luciferase activity by COUP-TFI 
is ERα dependent. In cells transfected with Taf1-ERα and pERE3, E2 induced a 
3.8-fold increase in reporter gene activity and cotransfection with 50 and 100 ng 
COUP-TFI expression plasmid significantly enhanced E2-induced luciferase 
activity. COUP-TFI coactivation of Taf1-ERα was comparable to that observed in 
cells transfected with wild-type ERα and COUP-TFI (Fig. 3-7 C). E2 also induced 
luciferase activity in COS-7 cells transfected with pERE3 and 19c-ERα;  
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Fig. 3-7 Coactivation of mutant ERα by COUP-TFI. (A) ERα variants. COS-7 cells 
transfected without ERα (B) or with Taf1-ERα (C), 19c-ERα (D), Null-hERa 
variant (E). After transfection cells were treated with DMSO or 10 nM E2 for 36 h., 
luciferase activity normalized to β-galacosidase activity was determined as 
described in the Materials and Methods. Fold induction was calculated relative to 
activity observed in cells treated with DMSO. Significant (p<0.05) induction by E2 
(*) or coactivation of E2-induced activity by COUP-TFI (**) is indicated.  
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Fig. 3-7. continued. 
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cotransfection with COUP-TFI also significantly enhanced E2-induced luciferase 
activity as shown in Figure 3-7 D. However, cells cotransfected pERE3, 
COUP-TFI and null-ERα, only minimal coactivation activity of COUP-TFI was 
observed (Fig.3-7 E). These data suggest that the functional helix 12 on AF-2 is 
not required for coactivation by COUP-TFI when the functional AF-1 of ERα is 
intact. However, when the AF-1 domain of ERα is deleted (i.e. 19c-ERα), the 
intact AF2 function is required for coactivation by COUP-TFI, and mutation of 
helix 12 amino acids (i.e. null-ERα) resulted in loss of coactivation activity. 
Metivier and coworkers previously reported that interactions between 
COUP-TFI and ERα enhanced the phosphorylation of ERα at Ser118 by 
increasing the affinity of ERα for interactions with ERK2, resulting in enhanced 
ERα transcriptional activity by COUP-TFI (215). However when COS-7 cells were 
transfected with pERE3 and an m118-ERα mutant which contains a Ser/Ala point 
mutation on Ser118 of ERα, E2 induced a 3.8-fold increase in reporter gene 
activity and cotransfection with 100 ng COUP-TFI expression plasmid 
significantly enhances E2-induced luciferase activity by 25-fold (Fig. 3-8 A). 
Furthermore, in COS-7 cells transfected with ERα, COUP-TFI and pERE3, 
treatment with the MAPK inhibitor PD98059, did not affect the enhancement of 
ERα-mediated transactivation by COUP-TFI (Fig. 3-8 B). These results show that 
mutation of the critical MAPK-dependent phosphorylation site (S118) in ERα did 
not result in loss of COUP-TFI coactivation activity, suggesting that there must be 
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another mechanism of ERα coactivation by COUP-TFI other than recruitment of 
ERK2/p42 MAPK and phosphorylation of the Ser 118 as previously reported in 
CHO-K1 cells (215).  
3.2.3 Interactions of ERα with COUP-TFI  
Interactions between COUP-TFI and ERα were investigated in a 
mammalian two-hybrid assay. HeLa cells were transfected with expression 
vectors for the GAL4 DBD (pM) or the chimeras of DBD fused to ERα (pM-ER) in 
the presence of the VP16 activation domain alone (VP16) or VP16 fused to the 
COUP-TFI (VP16–COUP),and pGAL45 (five tandem GAL4 response elements 
linked to a luciferase reporter gene). The results (Fig. 3-9 A) show that in the 
absence or present of E2 stimulation when cells transfected with pM-ER and 
VP16-COUP, the luciferase activity was significantly increased compared to the 
control luciferase values obtained with cells transfected with pM in the presence 
of VP16 or VP16–COUP, or pM-ER with VP16. The results show that in the 
absence of ligand VP16-COUP interacted with pM-ER and after addition of E2 
this interaction was increased. Thus results of the mammalian two-hybrid 
suggest that the interactions of COUP-TFI and ERα are ligand-independent but 
are also enhanced by E2.  
In this study we have shown that coactivation of ERα by COUP-TFI 
requires either AF-1 or AF-2 of ERα (Figs. 3-7 C-E). Therefore we used the 
mammalian two-hybrid assay to investigate interactions of COUP-TFI with 
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different domains of ERα in HeLa cells using VP-COUP and GAL4 DBD fusion 
proteins with the N-terminal A/B domains of ERα (pM-ER A/B) or with the C to F 
domains of ERα (pM-ER C/F). When cells were transfected with VP-COUP and 
pM-ER A/B, the luciferase activity was significantly increased compared to the 
control luciferase value in cells treated with DMSO or E2, suggesting that 
COUP-TFI interacts with A/B domain of ERα and the interactions are 
ligand-independent (Fig. 3-9 B). Furthermore, when VP-COUP was 
cotransfected with pM-ER E/F, the luciferase activity was only significant 
increased when cells were treated with E2, suggesting that COUP-TFI interacts 
with E/F domains of ERα and the interactions are ligand-dependent (Fig. 3-9 C). 
Interactions between ERα and COUP-TFI were also investigated in 
coimmunoprecipitation studies. His-tagged full-length COUP-TFI and ERα were 
cotransfected in COS-7 cells and treated with 10 nM E2. After 24-h, the cells 
were lysed and immunoprecipitated with an ERα antibody, and the presence of 
COUP-TFI in the immunoprecipitate was determined by Western blotting with a 
monoclonal antibody against His-tag. The results (Fig 3-9 D) show that 
COUP-TFI is coimmunoprecipitated by ERα antibodies; however COUP-TFI was 
not immunoprecipitated by ERα antibodies in cells transfected with either ERα or 
COUP-TFI alone or using control rabbit IgG Ab for immunoprecipitation (data not 
shown). These data further confirmed that COUP-TFI interacts with ERα in 
mammalian cells. 
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Fig. 3-8 Coactivation of ERα by COUP-TFI is not dependent on the ERK1/2 
pathway. (A) Coactivation of Taf1-ERα by COUP-TFI. COS-7 cells were 
transfected with pERE3, COUP-TFI, β-galactosidase and Taf1-ERα or serine 118 
ERα point mutant (m118-ER) expression plasmid. After transfection, cells were 
treated with DMSO or 10 nM E2 for 36 h., and luciferase activity normalized to 
β-galacosidase activity was determined as described in the Materials and 
Methods. (B) Effect of MAPK inhibitor PD 98059. COS-7 cells were transfected 
with pERE3, COUP-TFI, β-galactosidase and ERα expression plasmid as 
indicated. After transfection cells were treated with DMSO, 10 nM E2 or cotreated 
10 nM E2 with 20 μM PD 98059 for 36 h., and luciferase activity normalized to 
β-galactosidase activity was determined as described in the Materials and 
Methods. Fold induction was calculated relative to activity observed in cells 
treated with DMSO. Significant (p<0.05) induction by E2 (*) or coactivation of 
E2-induced activity by COUP-TFI (**) are indicated.  
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Fig. 3-9 Interactions of COUP-TFI and multiple regions of ERα. Interactions of 
COUP-TFI with wild-type ERα (A), ERα A/B domains variant (B) or ERα C/F 
domains variant(C) in mammalian two-hybrid assay. HeLa cells were 
cotransfected with 5XGAL reporter plasmid, β-galactosidase, either pVP16 (Vp16) 
or pVp16-COUP-TFI (VP16-COUP) and pM, pM-ER, pM-ER A/B or pM-ER C/F 
as indicated. After transfection cells were treated with DMSO or 10 nM E2 for 36 
h., and luciferase activity normalized to β-galacosidase activity was determined 
as described in the Materials and Methods and presented as relative luciferase 
units (RLU). Significant (p<0.05) interactions (*) are indicated. (D) Interactions of 
COUP-TFI and ERα in a co-immunoprecipitation assay. His-tagged COUP-TFI 
was transfected into COS-7 cells with or without ERα After transfection, cells 
were treated with 10 nM E2 for 24h., and cell extracts were immunoprecipitated 
(IP) with anti-ERα antibody and precipitates were then analyzed by Western blot 
(WB) using anti-His tag and anti-ERα antibodies as described in the Materials 
and Methods. 
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Figure 3-9 continued 
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3.2.4 Coactivation of ERα by COUP-TFI Deletion Mutants 
Previous studies in HeLa and rat urogenital mesenchymal (rUGM) cells 
showed that the DNA binding domain and the C terminus 35 amino acids of 
COUP-TFI are important for activation of Egr-1 (260). In contrast, the extreme C 
terminus region of COUP-TFI can act as a silencing domain and repress 
transcriptional activity by interactions with the SMRT and N-CoR (308). Domains 
of COUP-TFI required for coactivation of ERα were determined in MCF-7 and 
COS-7 cells cotransfected with ERα, pERE3, and wild-type or deletion mutants of 
COUP-TFI (Fig. 3-10 A). The mutants include dN1, dN2 and dN3 with N-terminal 
deletions of amino acids 1-72, 1-108 and 1-150 respectively; the C-terminal 
mutants dC1 and dC2 containing deletions of amino acids 370-420 and 269-420 
respectively. Analysis of the cellular localization of transfected COUP-TFI 
mutants by western immunoblots indicates that the deletion mutants also 
accumulate in the nucleus with only minimal levels detected in cytosolic extracts 
(Fig 3-10 B). 
The results in Figures 3-11 A and 3-11 B show that the overall patterns of 
coactivation of ERα by wild-type and variant COUP-TFI were similar in MCF-7 
and COS-7 cells. Decreased coactivation was observed in both cell lines 
transfected with dC1, dC2 and dN2. However, in MCF-7 cells some coactivation 
was observed whereas in COS-7 cells these mutations completely abrogated the 
coactivation response. In contrast dN1 coactivated and dN3 was inactive as a  
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Fig. 3-10 Multiple regions on COUP-TFI are required for coactivation of ERα. (A) 
Truncation mutants of COUP-TFI. (B) Cytosolic or nuclear localization of 
COUP-TFI deletion mutants. COS-7 cells were transfected with His-tagged 
COUP-TFI deletion mutants expressing plasmid, treated with 10 nM E2 for 36 h, 
harvested and fractionated for cytosolic (C) and nuclear (N) protein as described 
in Materials and Methods. 
 
     
 125
A. MCF-7 
dN3-NLS
dN2
dN1
dC2
dC1
WT
-
COUP-TFI 
Variants
0 2 4 6 8 10 12 14 16
DMSO
E2
*
**
*
**
**
**
**
Fold Induction
DA/B C E/F
DA/B C
DA/B C
DC E/F
D E/F
D E/F
   
 
B. COS-7 
dN3-NLS
dN2
dN1
dC2
dC1
WT
COUP-TFI 
Variants
-
0 50 100 150 200 250
Fold Induction
DMSO
E2
**
**
*
*
*
*
*
DA/B C E/F
DA/B C
DA/B C
DC E/F
D E/F
D E/F
 
 
 
Fig. 3-11 Coactivation of ERα by COUP-TFI deletion mutants. (A) MCF-7 or (B) 
COS-7 cells were transfected with pERE3, ERα, β-galactosidase and various 
truncation mutants of COUP-TFI expression plasmid. After transfection cells were 
treated with DMSO or 10 nM E2 for 36 h, luciferase activity normalized to 
β-galacosidase activity was determined as described in the Materials and 
Methods. Fold induction was calculated relative to activity observed in cells 
treated with DMSO. Significant (p<0.05) induction by E2 (*) or coactivation of 
E2-induced activity by COUP-TFI (**) is indicated. 
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coactivator in both cell lines. These data suggest that both the C-terminal aa 
370-420 and DNA binding domain of COUP-TFI are important for its activity as a 
coactivator of ERα.  
3.2.5 Coactivation of ERα by COUP-TFI Zinc-Finger Motif Mutants 
The role of the DBD of COUP-TFI in its activity as a coactivator of ERα 
was also investigated. There are two C4-type zinc-finger motifs in the DBD of 
COUP-TFI and three mutant constructs of COUP-TFI with Cys/Ala point 
mutations in the zinc finger motifs (m83, m103 and m138) were generated by 
site-direct mutagenesis (Fig. 3-12 A). The results of coactivation studies with 
wild-type and point mutant COUP-TFI constructs (Fig. 3-13) show that 
coactivation was decreased in cells transfected with the mutant constructs, 
suggesting that both C4-type zinc finger motifs on COUP-TFI are important for 
coactivation of ERα by COUP-TFI. Analysis of the cellular localization of 
transfected COUP-TFI mutants by western blots indicates that three point 
mutants (m83, m103 and m138) accumulated in the nucleus (Fig. 3-12 B). These 
data suggest that the loss of coactivation activity of COUP-TFI mutants is not 
caused by their failure to accumulate in the nucleus. 
The interactions between ERα and COUP-TFI point mutants were also 
investigated in coimmunoprecipitation studies. Three His-tagged DBD mutant 
constructs (m83, m103 and m138) were cotransfected along with ERα into COS-7 cells. 
Results of co-immunoprecipitation studies (Fig. 3-14) showed that ERα interacted with 
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lower affinity with the DBD mutants compared to interactions with wild-type COUP-TFI. 
These data suggest that the zinc finger motifs of COUP-TFI also play an important role 
in the interaction of this protein with ERα.   
3.2.6 Cooperative Coactivation of COUP-TFI with SRC-1 
Coactivators are critical nuclear proteins required for the functional activity 
of NRs, and they serve as bridging molecules between NRs and the basal 
transcriptional machinery (356). Coactivators may also directly affect chromatin 
structure or recruit other coactivators which modify chromatin structure and 
facilitate activation of target genes (20). Previous studies have shown that SRC-1 
interacts with COUP-TFI for activation of Egr-1 expression in HeLa cells and 
SRC-1 also interacts with and coactivates ERα-mediated transactivation, and this 
response is AF2-dependent (260). Therefore, we investigated the cooperative 
coactivation of ERα by COUP-TFI and SRC-1 in COS-7 cells transfected with 
ERα and pERE3 (Fig. 3-15). The results show that transfection of SRC-1 or 
COUP-TFI alone coactivated ERα-dependent transactivation by 6.7-fold or 
7.9-fold respectively and cotransfection with SRC-1 plus COUP-TFI expression 
plasmids gave greater than additive response and enhanced transactivation by 
18.1-fold indicating that COUP-TFI and SRC-1 cooperatively coactivated ERα. 
However, cotransfection with SRC-1 and the “inactivated” COUP-TFI deletion 
mutant dC1 in which aa 370-420 (c-terminal) have been deleted, show that the 
enhanced coactivation by SRC-1 (8.4-fold) was not significantly higher than 
observed in cells transfected with SRC-1 alone. These data suggest that the  
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Fig.3-12 Zinc finger motifs in the DNA binding domain of COUP-TFI are important 
for coactivation of ERα.  (A) Three different point mutations were made in the 
zinc finger motifs of COUP-TFI (C83A, C103A, C138A). (B) Cytosolic and 
nuclear localization of COUP-TFI variants. COS-7 cells were transfected with 
wild-type or mutant His-tagged COUP-TFI expressing plasmid, treated with 10 
nM E2 for 36 h, harvested and fractionated for cytosolic (C) and nuclear (N) 
protein as described in Materials and Methods. 
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Fig. 3-13 Coactivation of ERα by DBD point mutants of COUP-TFI  
COS-7 cells were transfected with pERE3, ERα, β-galactosidase and various 
zinc finger mutants of COUP-TFI expression plasmid. After transfection cells 
were treated with DMSO or 10 nM E2 for 36 h., and luciferase activity normalized 
to β-galacosidase activity was determined as described in the Materials and 
Methods. Fold induction was calculated relative to activity observed in cells 
treated with DMSO. Significant (p<0.05) induction by E2 (*) or coactivation of 
E2-induced activity by COUP-TFI (**) is indicated. 
     
 130
m138
+
COUP-TFIm103m83WTWT
ERα+++-
IP: ERα
WB: His-tag
WB: ERα
WB: His-tag
 
 
 
Fig. 3-14 The zinc finger motif of COUP-TFI is critical for protein-protein 
interactions with ERα. Wild-type or mutants His-tagged COUP-TFI were 
transfected into COS-7 cells with or without ERα. After transfection, cells were 
treated with 10 nM E2 for 24h., and cell extracts were immunoprecipitated (IP) 
with anti-ERα antibody and precipitates were then analyzed by Western blot (WB) 
using anti-His tag and anti-ERα antibodies as described in the Materials and 
Methods. 
     
 131
0
5
10
15
20
25
DMSO
E2
*
** **
**
**
Fo
ld
 In
du
ct
io
n
++----COUP-TFI dC1
+-+-+-SRC-1
--++--COUP-TFI
 
 
 
Fig. 3-15 Cooperative coactivation of ERα by COUP-TFI and SRC1.          
COS-7 cells were cotransfected with pERE3, ERα, β-galactosidase , COUP-TFI 
variants and SRC1 as indicated; cells were treated with DMSO or 10 nM E2 for 
36 h., Fold induction was calculated relative to activity observed in cells treated 
with DMSO. Significant (p<0.05) induction by E2 (*) or coactivation of E2-induced 
activity by COUP-TFI (**) is indicated. 
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C-terminal region of COUP-TFI is required for cooperative coactivation with 
SRC-1. 
3.2.7 Coactivation of ERα/Sp1 by COUP-TFI  
Several hormone-responsive genes in breast cancer cells are regulated 
through interactions of ERα/Sp1 with GC-rich promoter elements [285-298]. 
Results in Figure 3-16 show that E2 significantly induced luciferase activity in 
ZR-75 cells transfected with pSp13, a construct containing three consensus 
GC-rich Sp1 binding sites linked to luciferase. In cells also cotransfected with 
COUP-TFI expression plasmid (25, 50 or 100 ng) there was a significant increase 
in basal and E2-induced luciferase activity and there was also a > 3-fold 
enhanced induction response in cells cotransfected with 50 ng COUP-TFI 
expression plasmid. This represents one of the first examples of the coactivation 
of ERα/Sp1 in breast cancer cells.
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Fig. 3-16 Coactivation of ERα/Sp1 by COUP-TFI.  ZR-75 cells transfected with 
pSp13, ERα, β-galactosidase and increasing amounts of pCDNA3-COUP-TFI (0, 
25, 50 and 100 ng) expression plasmid. After transfection cells were treated with 
DMSO or 10 nM E2 for 36 h., luciferase activity normalized to β-galacosidase 
activity was determined as described in the Materials and Methods and 
presented as relative luciferase units (RLU). Fold induction was calculated 
relative to activity observed in cells treated with DMSO. Significant (p<0.05) 
induction by E2 (*) or coactivation of ERα/Sp1 by COUP-TFI (**) is indicated. 
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CHAPTER IV 
DISCUSSION AND CONCLUSION 
4.1 Mechanism of Induction of Egr-1 by E2 in MCF-7 cells 
Egr-1 is an immediate-early gene induced by mitogens in mammalian cells, 
and Egr-1 acts as a transcription factor that modulates expression of several 
genes (69, 72, 325). Several studies also suggest that Egr-1 can act as a tumor 
suppressor gene in some cells. For example, in a subclone of human HT1080 
fibrosarcoma cells, overexpression of Egr-1 inhibited transformed growth and 
[3H]thymidine uptake and suppressed the rate of tumor growth in athymic nude 
mice bearing HT1080 xenografts (138). Expression of Egr-1 was also relatively 
high in non-tumorigenic MCF-10A and 184A1N4 immortalized mammary 
epithelial cells, but low to non-detectable in ER-negative and ER-positive (ZR-75, 
T47D and MCF-7) breast cancer cells lines. A similar pattern of Egr-1 expression 
was also observed in rat mammary tissue (high) and mammary tumors (low), 
suggesting that loss of Egr-1 expression may be required for development of 
breast cancer. 
Pratt and coworkers previously reported that E2 induced Egr-1 gene 
expression in MCF-7 cells; this was accompanied by rapid autophosphorylation 
of raf-1. In this study, E2 also induced Egr-1 gene expression (mRNA and protein) 
in MCF-7 cells (Figs. 3-1 A and 3-5 B), and the mechanism of this response was 
further investigated using a series of constructs containing Egr-1 promoter inserts. 
     
 135
The -600 to +12 region of the Egr-1 gene promoter contains a GC-rich site, 
multiple SREs, and a cAMP response element (CRE). Previous studies indicate 
that both SRE and CRE motifs are hormone-responsive through ERα-dependent 
extranuclear induction of the src-ras-MAPK and PKA pathways (51, 85, 88, 219, 
220). In contrast, the more distal GC-rich Sp1 binding site could be activated by 
the non-classical nuclear ERα/Sp1 pathway (261). Deletion analysis (5'- and 3'-) 
of the Egr-1 gene promoter (Figs. 3-2 A and 3-2 B) indicates that SRE3 and 
SRE4 are E2-responsive and further mutation analysis (Fig. 3-2 C) demonstrates 
that E2-responsiveness is linked to the TCF and SRF motifs within SRE3. 
Previous studies in this laboratory showed that E2 also induced c-fos gene 
expression in MCF-7 cells through activation of a proximal SRE through the 
ras-MAPK pathway (88). Results in Figures 3-3 and 3-4 confirm that 
hormone-dependent activation of SRE3 in the Egr-1 promoter is also 
accompanied by Elk-1 phosphorylation and is inhibited by dominant negative 
Elk-1 expression. Thus, both immediate-early genes Egr-1 and c-fos are induced 
by E2 through activation of ras-MAPK by extranuclear pathways in breast cancer 
cells (88). 
Recent studies have shown that Egr-1 is regulated, in part, through the 
MAPK pathway in several cell lines (93, 151, 283). For example, in rat granulosa 
cells, gonadotropin-dependent upregulation of Egr-1 is dependent on multiple 
factors including MAPK and protein kinase A-dependent phosphorylation of 
factors associated with SRE1 and other proximal motifs (283). Activation of the 
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MAPK pathway is also required for light-induced upregulation of Egr-1 in the 
suprachiasmatic nucleus of mice (93) and hyperoxia-induced expression of Egr-1 
in mouse alveolar carcinoma cells (151). In the latter cell line, the MAPK inhibitor 
PD98059 blocked hyperoxia-induced expression of Egr-1, whereas PI3-K and 
p38 MAPK inhibitors had no effect. In the rat anterior pituitary gland and primary 
neonatal rat cardiomyocytes, hormonal activation of Egr-1 was MAPK-dependent 
and in cardiomyocytes, SREs were identified as putative hormone-responsive 
motifs (75, 203). In breast cancer cells, activation of PI3-K by E2 has been 
identified as an important pathway for proliferation of MCF-7 cells (50, 89, 328). 
Moreover, E2-mediated induction of c-fos through the SRE involved 
simultaneous activation of src-MAPK and src-PI3-K pathways where PI3-K 
activates the serum response factor (50, 88). We therefore investigated the role 
of PI3-K in the activation of Egr-1 mRNA expression by E2 (Fig. 3-5 C) and 
luciferase activity in cells transfected with pEgr-1E (Fig. 3-5 A). The results show 
that for both responses, E2-induced transactivation was inhibited by PD98059 
but not by the PI3-K inhibitor LY294002. Since E2 activates both MAPK and 
PI3-K pathways in breast cancer cells (49, 88, 93, 151, 220), the differential 
effects of the latter pathway on activation of Egr-1 and fos through their 
respective SREs may be due, in part, to promoter context.     
Ling and coworkers (195) investigated interactions of wild-type and variant 
Elk-1 and SRF with different SREs to form transcriptional-active ternary 
complexes. One type of SRE which is characteristic of the motif in the c-fos 
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promoter contains a "strong" SRF site (CArG) and a weak TCF (ets) site (Fig. 
4-1). In this model, SRF binds the SRE and recruits Elk-1, and both MAPK and 
PI3-K inhibitors block SRE-dependent transactivation. Another type of combined 
ets and CArG (CECI) motif has a high affinity TCF (or ets) site next to a weak 
CArG (SRF) site (195) (Fig. 4-1). In this model, Elk-1 binds the SRE and 
subsequently recruits SRF to form the transcriptional-active ternary complex. The 
TCF site in the Egr-1 promoter is identical to the corresponding "strong" motif in 
the CECI promoter. Thus, hormone-induced transactivation of Egr-1 requires 
MAPK-dependent activation of Elk-1 which interacts with a "strong" TCF site, and 
subsequent recruitment of SRF is not dependent on activation through the PI3-K 
pathway. Differential activation of c-fos and Egr-1 is also consistent with the 
growth-promoting activities of both c-fos and the PI3-K pathway in breast cancer 
cells (50, 89, 328), whereas Egr-1 is associated with suppression of breast 
cancer cell growth (138). In contrast, there is evidence that Egr-1 may enhance 
formation and growth of prostate cancer (26), and current studies are 
investigating the mechanisms that distinguish between the differential effects of 
Egr-1 in hormone-dependent breast and prostate cancer. 
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Fig. 4-1 Comparative SREs.  The SREs in the c-fos, CECI and Egr-1 gene 
promoters are given and the Ets (Elk-1 site) and SRF motifs are indicated [367]. 
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4.2 Coactivation of E2-Induced Transactivation by COUP-TFI 
The NR superfamily of transcription factors contains lignad-activated and 
orphan receptors that interact with genomic cis-element in target gene promoters 
to induce or repress gene expression (27, 123, 205, 235). Steroid hormone 
receptors such as ERα have been extensively used as models for determining 
the mechanisms of ligand-dependent receptor-mediated transactivation, which 
requires the assembly and recruitment of a nuclear complex of 
coactivators/coregulatory proteins (8, 9, 216, 235, 276). The p160/SRC family 
including SRC1/NCoA1, TIF2/GRIP1 and pCIP/AIB1/RAC3/ACTR/TRAM-1 was 
first discovered as coactivators of NRs that specifically interact with AF-2 of 
ligand-bound NRs (211). Sequence analysis of SRC proteins identified a basic 
helix-loop-helix (bHLH) domain and Per-Arnt-Sim (PAS) domains in the 
amino-terminal region, a centrally located receptor-interacting domain (RID) and 
a C-terminal transcriptional activation domain (AD) (Fig. 1-8). The RID which 
contains three conserved LXXLL motifs (NR box) appear to contribute to the 
specificity of coactivator-NR interaction. The histone acetyltransferase (HAT) 
activity was identified in C-terminal region of SRC-1. There are also activation 
domains that can interact with the CREB-binding protein (CBP) in C-terminal AD 
of SRC family (211). One mechanism by which the SRC family coactivates NRs 
resulted from studies on the interactions and recruitment of the CBP/p300 
coactivators which have intrinsic HAT activity that mediates the acetylation of 
nucleosome of histones, a covalent modification generally associated with the 
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enhancement of transcription [145,146]. Other proteins with the ability to modify 
histones or remodel chromatin structure include CARM1 (62), an arginine 
methytransferase, and ATP-dependent remodeling factors BRG1 and hBrm (84, 
143). These proteins have also been identified as coactivators of NRs. The 
multiprotein Mediator complexes known as the TRAP and DRIP complexes are a 
class of NR coactivators which also enhance transactivation by interactions with 
DNA-bound NRs and the RNA pol II transcriptional machinery to stabilize the 
formation of transcription PICs at the promoter [161]. DRIP205 and DRIP150 
have been shown to coactivate ERα-mediated transactivation in ZR-75 breast 
cancer cells (188, 368). Coactivation of ERα by DRIP205 does not require NR 
boxes and multiple domains of DRIP205 play a role in coactivation of ERα and in 
interactions with ERα (188, 368). Coactivation of ERα by DRIP150 also does not 
require NR boxes and a novel sequence (aa795-804) with putative α-helical 
structure is required for coactivation of ERα by DRIP150 (188, 368). Some 
unexpected molecules such as steroid-receptor-RNA activator-1 (SRA1), an 
RNA transcript, has been reported as a ligand-independent ERα coactivator in 
COS-1 cells (184). P68 (Ddx5) and p72 (Ddx17) which are RNA helicases have 
also been reported to act as transcriptional coactivators for ERα through ERα 
AF-1 by association with SRA and the AF-2 coactivator SRC1/TIF2 in MCF-7 and 
COS-1 cells (357). Coactivators identified to date are remarkable in both their 
number and diversity, suggesting that NR coactivation may involve more than 
one class of coactivators and the potential complexities associated with multiple 
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pathways are consistent with the subtle ligand-, tissue- and gene-specific action 
of NRs.  
COUP-TFI, one of the most studied of the orphan receptors, is involved in 
regulation of several important biological processes, such as neurogenesis, 
organogenesis, cell fate determination, and metabolic homeostasis (204, 205). 
The target genes for COUP-TF are summarized in Table 4-1. COUP-TFI acts as 
a transcription factor via COUP-TFI homodimers or as a heterodimer with RXR. 
In addition COUP-TFI interacts with other NRs such as RAR, TR, VDR,PPAR, 
and HNF4 and binds to a wide variety of response elements that contain 
imperfect AGGTCA direct repeats separated by a variable number of nucleotides 
(70, 343). COUP-TFI was initially identified as an activator of the chicken 
ovalbumin gene (290). In P19 embryonal carcinoma cells, COUP-TFI 
up-regulated vitronectin mRNA level and stimulated the vitronectin promoter 
activity in cells which overexpressed COUP-TFI (10). Recent studies showed that 
COUP-TFI activated transcription of the human CYP11B2 gene by binding to the 
-129/-114 promoter region of CYP11B2 in human adrenocortical H295R cells 
(306). Furthermore, there is increasing evidence showing that COUP-TF 
activates transcription through protein-protein interactions with DNA-bound 
transcription factors without a requirement for DNA binding. For example, 
COUP-TFI enhanced mRNA and protein expression levels of NGFI-A gene, also 
known as Egr-1 or Zif268, in HeLa and rUGM cells by interactions with Sp1. Both 
the DBD and the C terminus region of COUP-TFI are important for the NGFI-A 
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activation (260). COUP-TFI can also activate transcription as coactivators of 
other nuclear receptors. For example in HeLa cells, COUP-TFI interacts with 
another orphan receptor, hepatic nuclear factor 4 (HNF-4), for induction of 
phosphoenolpyruvate carboxykinase (PEPCK) gene transcription by 
glucocorticoids and the E/F domains of COUP-TFI are required for coactivation 
of HNF-4 (324). Recently, studies form different laboratories have shown that 
there is cross-talk between COUP-TFI and ERα where COUP-TFI modulates 
ERα-mediated gene expression (167, 169, 215, 252, 309). Melivler and 
coworkers reported that COUP-TFI formed a tight complex with ERα and 
enhanced ERα-dependent activity (215). The formation of a tight ERα-COUP-TFI 
intermediate complex resulted in an increased recruitment of ERK2/p42 MAPK to 
this complex resulting in phosphorylation of the ERα on Ser 118 in the A/B 
(N-terminal) region of ERα and this enhanced transcriptional activity of ERα. 
Coactivation of ERα by COUP-TFI can only take place in AF1 permissive cells 
such as HepG2, COS-7 and PC3 cells (i.e. cells in which ERα activity is driven 
mainly by AF1). Mutation of S118 of ERα impaired the effects of COUP-TFI on 
ERα-dependent activity (215). 
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Table 4-1 Target genes for COUP-TFs (307). 
Gonads LH receptor, FSH receptor ↓ 
Adrenal cortex CYP17 (17α-hydroxylase/17,20-lyaseP450) ↓ 
 CYP11B2 (Aldosterone synthase P450) ↑ 
 CYP19 (Aromatase P450) ↓ 
 DAX-1 ↓ 
Pituitary gland Oxytocin ↓ 
Cerebellum PCP-2 (Purkinje cell protein-2) ↓ 
Livers Angiotensinogen ↓ 
 HNF-1 (Hepatocyte nuclear factor-1) ↑ 
Heart ANF (Atrial natriuretic factor) ↑ 
Calreticulin (Ca2+ binding chaperone of the endoplasmic 
reticulum) ↑  
 NHE-1 (Na+/H+ exchanger-1) ↑ 
Adipose tissue PEPCK ↑ 
 LPL (Lipoprotein lipase) ↑ 
Prostate NGFI-A ↑ 
Others CaMKIV (Ca2+/ calmodulin-dependent protein kinase IV) ↓ 
 Vitronectin ↑ 
The arrows (↑) and (↓) indicate that COUP-TFs upregulate and down-regulate 
target genes, respectively. 
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The results of this study show that COUP-TFI coactivated ERα in cells 
transfected with pERE3 not only in COS-7 (AF-1 permissive) but also in MCF-7, 
HeLa and MDA-MB-231 cells (AF-2 permissive). Furthermore, in COS-7 cells 
cotransfected with pERE3, COUP-TFI and the S118A mutant of ERα, COUP-TFI 
enhanced E2-induced luciferase reporter activity (Fig. 3-8 A). Treatment of 
COS-7 cells with the MAPK inhibitor PD98059 did not affect the coactivation of 
E2-induced transactivation by COUP-TFI (Fig. 3-8 B). These data suggest that 
there is another mechanism of coactivation of ERα by COUP-TFI other than 
recruitment of ERK2/p42 MAPK and phosphorylation of the Ser 118 as 
previously reported by Melivler and coworkers (215). Results of this study clearly 
demonstrate that coactivation of ERα by COUP-TFI in both AF-1 and AF-2 
permissive cells (Figs.3-6 A-D), and mutation of the critical MAPK-dependent 
phosphorylation site (S118) in ERα does not result in loss of COUP-TFI 
coactivation activity.  
COUP-TFI, unlike most coactivators which are recruited by AF-2 of ERα, 
did not require the critical helix 12 region of ERα AF-2 for its coactivation of 
ERα-mediated transactivation in COS-7 cells since E2-induced activity in cells 
transfected with Taf-1ERα (Fig 3-7 C). COUP-TFI has minimal effect on 
coactivation of ERα when cells were transfected with pERE3 and null-ERα mutant 
which is an AF-1 deletion mutant also containing three point mutation on helix 12 
(Fig. 3-7 E), suggesting that the AF-1 of ERα is involved in coactivation by 
COUP-TFI. However, when COS-7 cells were transfected with 19c-ERα an AF-1 
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deletion mutant and pERE3, interestingly COUP-TFI has the same magnitude of 
ERα coactivation compared to cells transfected with wild-type ERα (Fig 3-7 D). 
These results suggest that the AF-2 of ERα is required for coactivation of ERα by 
COUP-TFI but only when AF-1 of ERα is deleted. The requirements of AF-1 or 
AF-2 of ERα for activity of COUP-TFI as a coactivator were further 
investigatigated for the roles of these regions of ERα for interactions with 
COUP-TFI. The results from mammalian two-hybrid assays showed that 
COUP-TFI interacts with the A/B domains of ERα in cells treated with DMSO and 
E2, suggesting that the interactions of COUP-TFI and A/B domains of ERα are 
ligand-independent (Fig. 3-9 B). COUP-TFI also interacts with the C/F domains 
of ERα but only when cells are stimulated with E2 (Fig. 3-9 C), suggesting that 
the interactions between COUP-TFI and AF-2 ERα are also induced by E2. In 
summary, both A/B domains which contain AF-1 and C/F domains which contain 
AF-2 of ERα are involved in coactivation function and physical interactions with 
COUP-TFI. 
We also investigated the functional and physical interactions of several 
N-terminal and point mutants of COUP-TF1 in transfection and 
co-immunoprecipitation assays (Figs. 3-11, 3-13 and 3-14). Deletion of amino 
acid 1-72 (dN1) did not affect the functional activity of COUP-TF1 as a 
coactivators, however, deletion of amino acids 1-108 resulted in loss of activity 
(Figs. 3-11 A and B). These results suggest that coactivation of ERα by 
COUP-TF1 in COS-7 and MCF-7 cells requires an intact DBD of COUP-TFI 
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and/or a small fragment of the A/B domain. A previous report in CHO cells also 
showed that the DBD of COUP-TFI was required for coactivation of ERα (215) 
and these results were consistent with those observed in COS-7 and MCF-7 cells 
(Fig. 3-11 A and B). The DBD of COUP-TF1 is similar to other nuclear receptors 
and contains two zinc finger motifs with multiple cysteine residues coordinated by 
zinc ions (Fig. 3-12 A). The importance of the zinc finger motifs in the activity of 
COUP-TFI as a coactivator was further investigating using cysteine mutants of 
COUP-TFI at amino acids 83 and 103 (in zinc finger 1) and 138 (zinc finger 2). In 
transfection studies, these COUP-TF1 point mutations (C83A, C103A and 
C138A) resulted in loss of coactivation activity for ERα (Fig. 3-13); moreover, in 
co-immunoprecipitation assays, these point mutations also reduced the 
interactions between COUP-TFI and ERα. The results form functional activity 
and physical interactions assays of COUP-TFI zinc-finger mutants suggest that 
zinc finger motifs of COUP-TFI are important for coactivation and interactions 
with ERα. 
Cooperative or synergistic coactivator-NR interactions involving two or 
more coactivators were previously reported (84, 112, 170, 357). CARM1 and 
PRMT1 enhanced ERα action only in the presence of GRIP1 (60, 170); 
CBP/p300 further increased coactivation of ERα by GRIP1 in CV-1 cells, and this 
was dependent on binding of both CBP/p300 and CARM1 to two different 
domains on GRIP1. Another study showed that ligand-dependent coactivation of 
ERα by SNURF cooperatively coactivated ERα with TATA-binding protein (TBP) 
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in ZR-75 breast cancer cells. Loss of cooperatively enhancement of 
ERα-mediated transactivation by cotransfection of TBP and RING domain mutant 
of SNURF resulted from interactions of TBP with the C-terminal RING domain of 
SNURF. Moreover, TBP did not cooperatively coactivate ERα in cells transfected 
with Δ1-20 SNURF (interacts with ERα but not DNA) or Δ31-65 SNURF (interacts 
with DNA but not ERα), suggesting that cooperative coactivation of ERα by 
TBP/SNURF is dependent on domains of SNURF that bind TBP, ERα, and DNA 
(298). Furthermore, coactivation of ERα in MCF-7 cells by SRC-1 and the RNA 
coactivator SRA are synergistically enhanced by p72, an RNA binding DEAD box 
protein that interacts with AF1-of ERα (357). COUP-TFI has been reported to 
cooperate with SRC-1 or p300 to enhance the transactivation of NGFI-A in HeLa 
cells (260). Also COUP-TFI associated with GRIP1 or SRC-1 to coactivate 
HNF-4-mediated transactivation of PEPCK in HeLa cells and the C-terminal 15 
amino acids are required for protein-protein interactions between COUP-TFI and 
the coactivators identified in a yeast two-hybrid assay (324). The results form this 
study showed that the deletion of C-terminal amino acids 370-420 (i.e. dC1 
COUP-TFI mutant) resulted in loss of coactivation activity (Fig. 3-11), however, 
this COUP-TFI mutant still interacted with ERα. These results are consistent with 
previous reports that the C-terminal region of COUP-TFI is important for 
coactivation with HNF-4 in HeLa cells (324). The function of C-terminal amino 
acids 370-420 was further investigated in cooperative coactivation with SRC-1 in 
COS-7 cells transfected with pERE3. In this study, (Fig. 3-15) it was shown that 
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SRC-1 and COUP-TFI cooperatively enhanced ERα-dependent transactivation; 
however, deletion of C-terminal region of COUP-TFI abolishes this cooperative 
activity, suggesting that aa 370-420 of COUP-TFI which are predicted to form a 
α-helix structure are important for interactions with SRC-1. 
ERα/Sp1-mediated transactivation has been linked to hormone activation 
of several genes involved in cell cycle progression, DNA synthesis and 
metabolism of purines and pyrimidines [285-298]. In vitro studies show that ERα 
interacts with both Sp1 and Sp3, and the C-terminal DBD of Sp1 is the major 
interaction site for ERα (299). Recently Kim et al used the FRET technique to 
investigate the interactions between ERα and Sp1 in living MCF-7 breast cancer 
cells. Results from FRET analysis showed that ERα interacts with Sp1 in living 
breast cancer cells and the interactions are ligand-dependent (162). COUP-TFI 
has been shown to interact with Sp1 in GST-pull down assay and activate 
NGFI-A expression through Sp1 GC-rich promoter elements in HeLa and rUGM 
cells (260). Only a few coactivators of ERα such as DRIP205, and DRIP150 have 
been reported as coactivators for ERα/Sp1 in ZR-75 breast cancer cells and 
research on identification of ERα/Sp1 coactivaors is in progress. The results of 
transfection assays in ZR-75 cells showed that COUP-TFI increased the basal 
luciferase activity of pSp13 (Fig. 3-16) which is consistent with previous reports 
showed that COUP-TFI interacted with Sp1 and up-regulated NGFI-A gene 
expression through interactions with Sp1 in HeLa and rug cells; furthermore 
COUP-TFI also enhanced E2-induced luciferase activity, suggesting that 
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coactivation of ERα/Sp1 by COUP-TFI was also observed in ZR-75 cells 
transfected with pSp13 (Fig. 3-16). The molecular mechanisms of this response 
are currently being investigated.  
In conclusion, we have shown here that COUP-TFI interacts with ERα and 
functions as a coactivator for ERα-mediated transactivation. The DNA binding 
domain of COUP-TFI is important for interactions with ERα and is also critical for 
its coactivation activity. COUP-TFI also functions as a coactivator for ERα/Sp1 
pathway in ZR-75 breast cancer cells.  
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